



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/00, A01N 43/04, 63/00, C12P 21/06</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/26911</b> <b>(43) International Publication Date:</b> 31 July 1997 (31.07.97)
<b>(21) International Application Number:</b> PCT/US97/01395 <b>(22) International Filing Date:</b> 29 January 1997 (29.01.97)  <b>(30) Priority Data:</b> 08/593,006      29 January 1996 (29.01.96)      US  <b>(60) Parent Application or Grant</b> (63) Related by Continuation US      08/593,006 (CIP) Filed on      Not furnished  <b>(71) Applicant (for all designated States except US):</b> GEORGETOWN UNIVERSITY [US/US]; 37th and O Street, N.W., Washington, DC 20057 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> DAVIDSON, Eugene, A. [US/US]; 5506 Nebraska Avenue, N.W., Washington, DC 20015 (US). YANG, Shutong [CN/US]; Apartment 5, 4115 W Street, N.W., Washington, DC 20007 (US).  <b>(74) Agent:</b> COLEMAN, Henry, D.; McAulay Fisher Nissen Goldberg & Kiel, L.L.P., 261 Madison Avenue, New York, NY 10016 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> MALARIA VACCINE BASED UPON THE ADDITION OF A MSA1 PEPTIDE  <b>(57) Abstract</b> <p>The present invention relates to a malaria chimeric peptide comprising a vaccinia virus system which expresses a protein corresponding substantially to the major merozoite surface antigen 1 (MSA1) of <i>Plasmodium falciparum</i> or an immunogenic portion, thereof. In preferred embodiments, the MSA1 peptide is a 593 amino acid peptide corresponding to amino acids 1047 to 1640 of MSA1 and is combined with a signal peptide and/or an anchor peptide. Chimeric peptides having both signal and anchor sequences in combination with MSA1 sequences were the most effective in eliciting an immunogenic response from a vaccinated host.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

## Malaria Vaccine Based Upon the Addition of a MSA1 Peptide

### Field of the Invention

The present invention relates to novel DNA constructs comprising a vector linked to a DNA segment which encodes a protein containing a signal protein at its N-terminus and an anchor sequence at its C-terminus.

More particularly, the present invention relates to vaccines which are useful for the prevention and treatment of malaria caused by Plasmodium falciparum in humans.

This work was supported by a DARPA grant. The government retains certain rights in the invention.

### Background of the Invention

Preventing or treating malaria has long been a challenging health problem, particularly in developing countries, and the rapid development of drug resistance in the parasite has enhanced the need for the development of a malaria vaccine. Although there has been steady progress over the last decade, several problems still must be overcome, including selection of an appropriate delivery system vehicle and antigen carrier.

Although malaria was believed to have subsided after World War II, recent outbreaks suggest that the disease is on the rise. Malaria is again the leading cause of morbidity/mortality globally and presents an increasing threat in at risk environments. Estimates are that 300 million new cases of malaria occur each year, with mortality of approximately 1% of infected individuals. Prophylactic medications used to prevent the disease have been rendered ineffective by the emergence of drug-resistant strains of the parasite worldwide. Complete vector protection is simply not possible and all attempts to eradicate the relevant species of mosquito have failed.

Four species of protozoa of the genus Plasmodium are

found in man. The four species include: Plasmodium vivax, Plasmodium malariae, Plasmodium falciparum and Plasmodium ovale. Of these, Plasmodium falciparum produces the most pathogenic of the malarias and often results in death. It is responsible for about half of the human cases of malaria found worldwide.

In malaria, the disease is such that infection followed by recovery does not confer meaningful protection to the individual despite a significant antibody response to several of the parasite proteins. The conventional wisdom has been that the parasite either does not possess antigens suitable for the development of a protective response or has evolved mechanisms which allow it to escape the host immune system. Because recent evidence has shown that immune protection is possible using irradiated sporozoites, the latter hypothesis described above is the more reasonable explanation.

The life cycle of the malaria parasite provides several stages at which interference could lead to cessation of the infective process. Included among these stages is the invasion of the erythrocyte by the merozoite. The merozoite represents a potentially attractive target (and perhaps the only target) from which a vaccine may be produced, because the free merozoite, although it has a limited lifetime (one to two hours) occurs earlier in the life cycle of malaria, and the emergence of later stage sexual forms, which are responsible for transmission of the disease, depends upon the erythrocytic stage.

The general life cycle of malaria parasites is the same for human and other animal malaria parasites, thus allowing model studies to be conducted on a rodent species with accurate translation to the human parasite. For example, the rodent malaria parasite strain Plasmodium berghei Anka has a pathology very similar to the FCR-3 strain of Plasmodium falciparum (a well studied variant of the human parasite). In addition, the blood stage of the human parasite can be grown in the laboratory (in human red cells) thus affording a system

for studying the effects of antibodies/inhibitors on the invasion process, and the erythrocytic phase.

In the life cycle of the malaria parasite, a human becomes infected with malaria from the bite of a female Anopheles mosquito. The mosquito inserts its probe into a host and in so doing, injects a sporozoite form of Plasmodium falciparum, present in the saliva of the mosquito.

The sporozoites which have been injected into the human host are cleared into a number of host tissue cells, including liver parenchyma cells (hepatocytes) and macrophages. This phase is known as the exoerythrocytic cycle because at this point in the life cycle the organism has not yet entered red blood cells. After entering hepatocytes, sporozoites undergo a transformation into trophozoites, which incubate and undergo schizogony, rupture and liberate tissue merozoites. This process takes approximately 7-10 days and, depending upon species, may repeat itself several times, during which time the host feels no effects. In Plasmodium falciparum, this repetition does not occur. After the incubation period, the liver or other tissue cells burst open and release numerous merozoites into the bloodstream.

Shortly thereafter, certain of these blood borne merozoites invade red blood cells, where they enter the erythrocytic phase of the life cycle. Within the red blood cells, young plasmodia have a red nucleus and a ring-shaped, blue cytoplasm. The plasmodium divides into merozoites, which may break out of the red blood cell, enter other erythrocytes and repeat the multiplication process. This period lasts approximately 48 hours.

During this same 48 hour period of the erythrocytic cycle, male and female gametocytes are formed in the red blood cells. These gametocytes also burst out of the red blood cells along with the merozoites. It is during this period that the human host experiences the symptoms associated with malaria. The merozoites which burst forth from the red blood

cells live for only a few hours in the bloodstream. The gametocytes live for several days or more in the host's bloodstream.

The gametocytes are capable of mating only in the mosquito. Thus, in order for Plasmodium falciparum to produce sporozoites for infecting a second human host, a mosquito must first bite a human host carrying gametocytes. These gametocytes mature into macrogametes, mate in the mosquito's stomach and produce a zygote. The zygote (ookinete) is active and moves through the stomach or the midgut wall. Under the lining of the gut, the ookinete becomes rounded and forms a cyst called an oocyst, in which hundreds of sporozoites develop. Sporozoites thereafter invade the entire mosquito and many of them enter the salivary glands where they are in a favorable position to infect the next host when the mosquito feeds on its blood. The life cycle thereafter simply repeats itself in another human host.

During the life cycle of Plasmodium falciparum, inhibition of invasion of the erythrocyte by the merozoite may be a key to developing an effective vaccine for malaria. Once the parasite has gained entry into the red cell, exposure to the immune system is gone.

In the past, live vaccinia virus was used as a vaccine to eradicate smallpox successfully, and a recombinant vaccinia virus expressing viral antigens has been shown to induce a strong antibody response in immunized animals, conferring protection against disease (Arita, I., Nature, 1979, 279, 293-298). Furthermore, it has been shown in animal models that co-presentation of potential immunogens with highly immunogenic vaccinia virus proteins can elicit a strong immune response against that specific immunogen (Moss and Flexner, Annals of the New York Academy of Sciences, 86-103; Mackett and Smith, J. Gen. Virol., 1986, 67, 2067-2082; Houard, et al., J. Gen. Virol., 1995, 76, 421-423; Fujii, et al., J. Gen. Virol., 1994, 75, 1339-1344; Rodrigues, et al. J. Immunol., 1994, 153, 4636-4648). Therefore, the utilization of live

recombinant vaccinia virus as a vaccine might overcome many problems of antigen expression and delivery presently encountered in the preparation of recombinant proteins in E. coli, yeast or insect expression systems. A panel of transfer vectors have been constructed that allow insertion of foreign genes into several sites within the 180kb vaccinia virus genome (Earl and Moss, Current Protocols in Molecular Biology, 1993, 16.17.1-16.17.16). Also, it has been reported that >25kb of foreign DNA can be inserted into the vaccinia virus genome (Smith and Moss, Gene, 1983, 25, 21-28). The correct processing (Chakrabarta, et al., Nature, 1986, 320, 535-537) and the appropriate post-translational modification (Hu, et al., Nature, 1986, 320, 537-540; Ball, et al., Proc. Natl. Acad. Sci. USA, 1986, 83, 246-250; de la Salle, et al., Nature, 1985, 316, 268-270), transport and secretion (Ball, et al., Proc. Natl. Acad. Sci. USA, 1986, 83, 246-250 and Langford, et al., Mol. Cell. Biol. 1986, 6, 3191-3199) are dictated by the primary structure of the expressed protein. In addition, a recombinant vaccinia virus vaccine has the advantage of being relatively inexpensive and easily stored, transported and delivered, features which are particularly important in the developing countries where malaria is most prevalent.

Proteins on the surface of merozoites are good targets for an immune response and are good malaria vaccine candidates because merozoites are the only stage in the asexual blood cycle in which the parasite is exposed to the immune system. The 190kD glycoprotein of *Plasmodium falciparum*, precursor to major merozoite surface antigen1 (MSA1), which is synthesized during schizogony, is considered a promising candidate for a blood-stage malaria vaccine (Blackman, et al., Mol. Biochem. Parasitol., 1991, 49, 29-34; Perrin, et al., J. Exp. Med., 1984, 160, 441-451; Siddiqui, et al., Proc. natl. Acad. Sci. USA, 1987, 84, 3014-3018; Perrin, et al., Immunol. Rev., 1982, 61, 245-269). The high-molecular weight precursor is processed into 88kD, 30kD, 38kD and 42kD fragments which remain as complexes on the merozoite surface (Holder, et al., Parasitology, 1987, 94, 199-208; McBride and Heidrich, Mol.

Biochem. Parasitol., 1987, 23, 71-84). The complex is released from the membrane by cleavage of the 42kD anchor fragment, and a 19kD carboxyl-terminal fragment remains on the merozoite membrane and is carried into the invaded erythrocytes (Blackman, et al., supra; Blackman, et al., Mol. Biochem. Parasitol., 1991, 49, 35-44). The complete MSA1 of unprocessed *P. falciparum* has been used to provide partial or complete protection against challenge infection (Blackman, et al., Mol. Biochem. Parasitol., 1991, 49, 29-34; Perrin, et al., J. Exp. Med., 1984, 160, 441-451; Siddiqui, et al., Proc. natl. Acad. Sci. USA, 1987, 84, 3014-3018), and it is highly immunogenic in humans (Perrin, et al., Immunol. Rev., 1982, 61, 245-269). Rabbit antibody against the C-terminal processing fragment of MSA1, as expressed in baculovirus, strongly inhibits parasite growth in vitro. These antibodies were able to inhibit homologous and heterologous parasites with similar degrees of efficiency (Hui, et al., Infect. Imm., 1993, 61, 3403-3411).

In prior work at Georgetown University, a series of monoclonal antibodies (mAbs) directed against glycophorin A, the putative erythrocyte receptor for *P. falciparum* were prepared. One of these mAbs, designated 2B10 is capable of blocking the binding of MSA1 to human erythrocytes and inhibiting the invasion of *P. falciparum* merozoites into human erythrocytes (Su, et al. Infect. Imm., 1993, 151, 2309). The anti-idiotypic antibody of 2B10 recognized the C-terminal (1047-1640aa) region of MSA1 in a western blot (Su, et al., J. Immunol., 1995) and appears to recognize the same site on glycophorin A as the merozoite.

#### Summary of the Invention

The present invention relates to a malaria vaccine comprising an expression vector, preferably, a vaccinia virus system which expresses a protein corresponding substantially to a specific domain of the major merozoite surface antigen 1 (MSA1) of *Plasmodium falciparum* or an immunogenic peptide portion thereof.



In this preferred vaccinia virus system, the DNA coding for the MSA1 protein domain is expressed by the vaccinia virus after administration to a patient. The MSA1 protein or sub-fragment which is then expressed in the patient raises a humoral and/or cell-mediated response to the merozoite malaria antigen, which response provides the effect of protecting the vaccinated patient from a subsequent malaria infection. In preferred embodiments according to the present invention, the vaccinia virus system continues to express antigen in the patient for a period of days, months or even years, thus reinforcing the immunogenic response of the patient to the expressed antigen.

The MSA1 peptide antigen or immunogenic peptide portion thereof which is expressed by the expression vector vaccinia virus may also comprise a signal peptide and/or an anchor peptide sequence. It has been found that the addition of a signal and/or anchor peptide to the expressed MSA1 antigen in vaccines according to the present invention unexpectedly enhances the immunogenicity to the patient of the MSA1 protein of Plasmodium falciparum. It is an unexpected result that the inclusion of a signal and/or anchor protein with MSA1 can be expressed by a vaccinia virus system according to the present invention and the expressed peptide will produce a significantly greater immunogenic response than the MSA1 peptide alone or in combination with an adjuvant. It is also an unexpected result that the inclusion of a signal and anchor sequence in the MSA1 peptide sequence expressed by the vaccinia virus will produce an immunogenic response which may be as much as 100 fold greater than the immunogenic response which is produced by the MSA1 peptide which does not contain a signal or anchor peptide sequence.

Methods of inducing an immunogenic response in a patient are also contemplated by the present invention. In this method, a patient is administered an amount of a vaccinia virus capable of expressing the MSA1 peptide of Plasmodium falciparum such that the patient develops an immunogenic

response to the expressed peptide. The immunogenic response generated preferably will be "substantially protective", i.e., will protect the patient from some of the more severe symptoms and physiological states of the malaria disease, including the death of the patient from malaria.

The present invention also relates to an immunogenic dosage form as a vaccine, for inducing an immunogenic response to the merozoite stage in the life cycle of Plasmodium falciparum. Methods of vaccinating a patient against a malaria infection are also contemplated by the present invention. In this method, a patient is vaccinated against a Plasmodium falciparum infection by administering an immunogenic response producing effective amount of a vaccinia virus capable of expressing the MSA1 peptide or an immunogenic peptide portion thereof of Plasmodium falciparum in the patient.

The present invention also relates to chimeric proteins or peptides comprising the peptide sequence corresponding to the major merozoite surface antigen 1 (MSA1) of Plasmodium falciparum or an immunogenic peptide portion thereof in combination with a signal sequence and/or anchor sequence, more preferably both a signal sequence and an anchor sequence.

#### Description of the Figures

Figure 1 is a diagrammatic representation of the construction of recombinant vaccinia viruses incorporating the sequences corresponding to MSA1C-(Si,A), MSA1C-(Si,nA), MSA1C-(nSi,A) and MSA1C-(nSi,nA).

Figures 2-5 represent the gene sequences for MSA1C-(Si,A), MSA1C-(Si,nA), MSA1C-(nSi,A) and MSA1C-(nSi,nA).

Figure 6 is a diagrammatic representation of four recombinant vaccinia viruses of the present invention: rv-MSA1-(Si,A); rv-MSA1-(Si,nA); rv-MSA1-(nSi,A); rv-MSA1-(nSi,nA). This figure shows the schematic of the genome of recombinant vaccinia viruses expressing the different MSA1

constructs.  $Tk_L$  and  $Tk_R$ , right and left regions of the vaccinia virus thymidine kinase gene; LacZ, beta-galactosidase gene. Si: signal region of MSA1; nSi: no signal region of MSA1; A: anchor region of MSA1; nA: no anchor region.

Figure 7 is a diagrammatic representation of the results obtained from Western blot analysis of recombinant vaccinia virus expressed proteins using anti-MSA1C-A mouse serum as a probe, of proteins expressed from BSC-1 cells infected with vaccinia virus. A. pellet of rV.V-MSA1C(Si,nA) infected cells; B. supernatant of rV.V-MSA1C(Si,nA) infected cells; C. pellet of rV.V-MSA1C(Si,A) infected cells; D. supernatant of rV.V-MSA1C(Si,A) infected cells; E. pellet of rV.V-MSA1C(nSi,nA) infected cells; F. supernatant of rV.V-MSA1C(nSi,nA) infected cells; G. pellet of rV.V-MSA1C(nSi,A) infected cells; H. supernatant of rV.V-MSA1C(nSi,A) infected cells; I. pellet of WR infected cells; J. supernatant of WR infected cells.

Figure 8 is a diagrammatic representation of results obtained from immunofluorescence staining of non-permeabilized infected cells. HeLa cells seeded on pre-treated coverslips for 48 hours were infected with recombinant and wild-type vaccinia virus at an M.O.I. of 5. The cells were probed with anti-MSA1C-A serum and labeled with FITC goat anti-mouse. A,B: rV.V-MSA1C(Si,nA) infected cells; C,D: rV.V-MSA1C(Si,A) infected cells; E,F: rV.V-MSA1C(nSi,nA) infected cells; G,H: rV.V-MSA1C(nSi,A) infected cells; I,J: WR infected cells.

Figure 9 is a diagrammatic representation of results obtained in rabbits immunized intradermally with the recombinant vaccinia viruses of the present invention. Five rabbits were immunized intradermally with recombinant and wild-type vaccinia virus, and one rabbit was immunized intravenously with rV-MSA1C-(Si,A). The I.D. immunizations occurred on days 0, 21, 47 and 68, and the I.V. immunizations occurred on days 0, 47 and 68. Blood samples taken on days 33, 54, and 78 were analyzed for antibodies to the trpE-MSA1C-A protein (C-terminus of MSA1 expressed and purified from E.

coli) using ELISA. Sera were analyzed in duplicate. (+)rV-MSA1C-(Si,A); (▲)rV-MSA1C-(Si,A); (o)rV-MSA1C-(Si,nA); (X)rV-MSA1C-(nSi,nA); (◆)rV-MSA1C-(nSi,A); (∫)WR.

Figure 10 is a diagrammatic representation of results obtained in Balb/c mice which were inoculated with vaccinia viruses of the present invention. Balb/c mice were inoculated I.P. with recombinant and wild-type vaccinia virus on days 0, 21, 42 and 63. Blood samples taken on days 11, 31, 51, 73, 93, 123, 147, 167 and 187 were analyzed for antibodies to trpE-MSA1C-A protein (C-terminus of MSA1 expressed and purified from E. coli) using ELISA. Sera were analyzed in duplicate: (∫) rV-MSA1C-(Si,A); (o) (rV-MSA1C-(Si,nA); (X) (rV-MSA1C-(nSi,A); (◆) (rV-MSA1C-(nSi,nA); (+) WR.

Figure 11 is a diagrammatic representation of the results obtained from a Western blot analysis of the recognition of a 190kD of P. falciparum by vaccinia virus induced mouse antibodies. Schizont stage parasites were lysed by boiling in sample buffer and loaded onto a 4-20% Tris-glycine gradient gel, and the proteins were transferred to a PVDF membrane by electrophoresis. These blots were then probed with anti-MSA1C-(Si,A), anti-MSA1C-A or anti-WR antibodies and labelled with phosphatase-conjugated goat anti-mouse IgG. A. anti-MSA1C(Si,A); B. anti-MSA1C-A; C. anti-WR.

### Detailed Description of the Invention

The following terms shall be used throughout the instant specification in an effort to describe the present invention.

The term "chimeric protein", "chimeric peptide" or "chimeric peptide sequence" is used to describe the non-natural peptide sequences according to the present invention which comprise the expressed protein or peptide and an anchor peptide and/or a signal peptide. As noted by the use of this term, chimeric peptides generally are synthetic peptides pro-

duced by an expression vector which contain a desired target protein or peptide (either MSA1 or an immunogenic peptide portion thereof) in combination with another peptide sequence (either an anchor or signal peptide sequence).

The term "patient" is used to describe an animal, including a mammal and especially including a human patient which is administered a dosage form of an expression vector or chimeric protein according to the present invention. In the present invention, the expression vector encodes for MSA1 or an immunogenic peptide portion thereof and expresses the encoded protein or peptide in the patient.

The term "expression vector" is used to describe the means by which nucleic acid, including DNA, cDNA, RNA or variants thereof, more preferably DNA fragments, encoding for a specific peptide or protein, may be introduced into the patient or the patient's tissue in order to express or produce the desired protein. Such vectors include any vectors into which a nucleic acid sequence encoding for the desired MSA1 protein or immunogenic peptide fragment thereof, anchor peptide sequence and/or, signal protein sequence may be inserted (along with any required or optional operational elements) into a host organism and replicated. Expression vectors may also be used to simply produce chimeric peptide in culture for isolation. Preferred vectors are those which are capable of expressing the peptide or protein sequences in mammalian cells and whose restriction sites are well known and which contain the required operational elements for expression of the desired protein or peptide sequence. In the present invention, the vector is preferably a vaccinia virus vector, adenovirus vector or herpes virus vector which has the capacity to infect a mammalian cell and express or synthesize proteins utilizing the host's biosynthetic mechanism. In such cases, the viral vector used for delivery should optimally be one which infects cells but which does not cause lysis due to replication (i.e., an attenuated or partially disabled virus selected from among adenovirus, vaccinia virus and herpes viruses, among similar types).

According to the vector approach in the present invention, the vector will infect the host cells and, using the host cells' biosynthetic pathways, synthesize encoded protein or peptide fragment. Any immunizing vehicle which has a detailed genetic and human use history may be used as the expression vector in the present invention. The preferred expression vector is a viral vector, more preferably, a vaccinia virus vector, for example, as described by Earl and Moss, Current Protocols in Molecular Biology, 1993, 16.17.1-16.17.16) and Smith and Moss, Gene, 1983, 25, 21-28. However, any vaccinia or other viral vector which may be used in the above-described manner may be appropriate for use in the present invention.

In order to express the desired protein or peptide sequence, the expression vector should contain at least one promoter, at least one operator, at least one terminator codon, and any other sequences which are necessary for the efficient transcription and subsequent translation of the nucleic acid from the vector. These operational elements are well known to those of ordinary skill in the art. In preferred embodiments according to the present invention, the expression vectors will advantageously comprise at least one origin of replication which is recognized by the host organism along with at least one selectable marker and at least one promoter sequence capable of initiating transcription of the nucleic acid (preferably, DNA) sequence.

The term "vaccine" is used throughout the specification to describe a preparation intended for active immunological prophylaxis. In the present invention, vaccines comprise an expression vector, preferably a vaccinia virus system which expresses an antigenic protein after administration of the vaccinia virus system to an animal, such as a mammal. Vaccines may also comprise chimeric peptides comprising MSA1 or an immunogenic peptide portion thereof in combination with a signal peptide sequence and/or an anchor peptide sequence. The method of administering the vaccine(s) according to the

present invention may vary and include intravenous, buccal, oral, transdermal and nasal, among others, but intramuscular or subcutaneous administration is the most common method of administration.

The term "MSA1 protein" or "MSA1 peptide" is used to describe the major merozoite surface antigen 1 of the merozoite stage of Plasmodium falciparum or immunogenic peptide portions thereof. MSA1 is the major surface protein of the merozoite stage of Plasmodium falciparum. It is a 190kD glycoprotein which is synthesized during schizogony life-cycle stage. The high molecular weight precursor is processed into 88kD, 30kD, 38kD and 42kD fragments which remain as complexes on the merozoite surfaces. The complex is released from the merozoite membrane by cleavage of the 42kD anchor fragments and a 19kD carboxy-terminal fragment remains on the merozoite membrane and is carried into the invaded erythrocytes. The complete MSA1 gene sequence is available on the data base UNDP/WORLDBANK/WHO/TDR Malaria Sequence. The preferred portion of MSA1 for expression in the vaccinia virus system according to the present invention is a carboxy-terminal region (corresponding to amino acids 1047 to 1640) of MSA1. In the present invention, the expressed protein may be MSA1 or any portion thereof, preferably such that the MSA1 portion contains at least the carboxy-terminal region of MSA1.

The terms "carboxy-terminal region of MSA1" and "carboxy-terminal MSA1 peptide" are used to describe that portion of the MSA1 protein corresponding to amino acids 1047 to 1640 which is the preferred expressed antigen peptide sequence in the present vaccines. It represents a preferred target for the development of humoral and/or cell mediated response because of the degree of specificity of the immune response which can be elicited against such a protein segment. In the present invention, the expression of the C-terminal MSA1 peptide according to the instant invention produces a specific immune reactivity which becomes less specific as more of the MSA1 protein is incorporated into the vaccinia virus system. In the present invention, the above terms to

d\escribe the C-terminal MSA1 peptide include not only the 593 amino acid peptide referred to above, but any peptide substantially corresponding to that 593 amino acid peptide.

The following DNA sequence corresponding to the C-terminus is preferably used in the present invention:

```
TTGAATTC ACTTAATAAC CCAAAGCATG TATTACAAAA CTTTCTGTT
TTCTTTAACA AAAAAAAGA AGCTGAAATA GCAGAACTG AAAACACATT
AGAAAACACA AAAATATTAT TGAAACATTA TAAAGGACTT GTTAAATATT
ATAATGGTGA ATCATCTCCA TTA AAAACTT TAAGTGAAGA ATCAATTCAA
ACAGAAGATA ATTATGCCAG TTTAGAAAAAC TTTAAAGTAT TAAGTAAATT
AGAAGGAAAA TTAAAGGATA ATTTAAATTT AGAAAAGAAA AAATTATCAT
ACTTATCAAG TGGATTACAT CATTTAATTG CTGAATTAAA AGAAGTAATA
AAAAATAAAA ATTATACAGG TAATTCTCCA AGTGAAAATA ATACGGATGT
TAACAATGCA TTAGAATCTT ACAAAAAATT TCTCCAGAA GGAACAGATG
TTGCAACAGT TGTAAGTGAA AGTGGATCCG ACACATTAGA ACAAAGTCAA
CCAAAGAAAC CAGCATCAAC TCATGTAGGA GCAGAGTCTA ACACAATAAC
AACATCACAA AATGTCGATG ATGAAGTAGA TGACGTAATC ATAGTACCTA
TATTTGGAGA ATCCGAAGAA GATTATGATG ATTTAGGACA AGTAGTAACA
GGAGAAGCAG TAACTCCTTC CGTAATTGAT AACATACTTT CTAAAATTGA
AAATGAATAT GAGGTTTTAT ATTTAAAACC TTTAGCAGGT GTTTATAGAA
GTTTAAAAAA ACAATTAGAA AATAACGTTA TGACATTTAA TGTTAATGTT
AAGGATATTT TAAATTCACG ATTTAATAAA CGTGAAAATT TCAAAAATGT
TTTAGAATCA GATTTAATTC CATATAAAGA TTAAACATCA AGTAATTATG
TTGTCAAAGA TCCATATAAA TTTCTTAATA AAGAAAAAAG AGATAAATTC
TTAAGCAGTT ATAATTATAT TAAGGATTCA ATAGATACGC ATATAAATTT
TGCAAATGAT GTTCTTGGAT ATTATAAAAT ATTATCCGAA AAATATAAAT
CAGATTTAGA TTCAATTAAA AAATATATCA ACGACAAACA AGGTGAAAAT
GAGAAATACC TTCCCTTTTT AAACAATATT GAGACCTTAT ATAAAACAGT
TAATGATAAA ATTGATTTAT TTGTAATTCA TTTAGAAGCA AAAGTTCTAA
ATTATACATA TGAGAAATCA AACGTAGAAG TTAAAATAAA AGAACTTAAT
TACTTAAAAA CAATTC AAGA CAAATTGGCA GATTTTAAAA AAAATAACAA
TTTCGTTGGA ATTGCTGATT TATCAACAGA TTATAACCAT AATAACTTAT
TGACAAAGTT CCTTAGTACA GGTATGGTTT TTGAAAATCT TGCTAAAACC
GTTTTATCTA ATTTACTTGA TGGAACTTG CAAGGTATGT TAAACATTTT
ACAACACCAA TGCGTAAAAA AACAATGTCC ACAAATTCT GGATGTTTCA
GACATTTAGA TGAAAGAGAA GAATGTAAAT GTTTATTAAA TTACAAACAA
GAAGGTGATA AATGTGTTGA AAATCCAAAT CCTACTTGTA ACGAAAATAA
```



TGGTGGATGT GATGCAGATG CCAAATGTAC CGAAGAAGAT TCAGGTAGCA  
ACGGAAAGAA AATCACATGT GAATGTACTA AACCTGATTC TTATCCACTT  
TTCGATGGTA TTTTCTGCAT TTCCTCTAAC TTCTTAGGAA TATCATTCTT  
ATTAATACTC ATGTTAATAT TATACAGTTT CATTTAA

The amino acid sequence corresponding to the above-described C-terminus of MSA1 is:

KLNSLNNPKHVLQNFSVFFNKKKEAIEAETENTLENTKILLKHYKGLVKYYNGE  
SSPLKTLSEESIQTEDNYASLENFKVL SKLEGKLDNLNLEKKLSYLSSGLHHLIAELKEV  
IKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVSESGSDTLEQSQPKKPASTHVGA  
ESNTITTSQNVDDDEVDDVIIIVPIFGESEEDYDDLQGVVTGEAVTPSVIDNILSKIENEYEVL  
YKPLAGVYRSLKKQLENNVMTFNVNVKDILNSRFNKRENFKNVLES DLIPYKDLTSSNYVV  
KDPYKFLNKEKRDKFLSSYNYIKDSIDTDINFANDVLGYKILSEKYKSDLD SIKKYINDKQ  
GENEKYLPFLNNIETLYKTVNDKIDLFVIHLEAKVLNNTYEKSNVEVKIKELNYLKT IQDKL  
ADFKKNNNFVGIADLSTDYNHNNLLTKFLSTGMVFENLAKTVLSNLLDGNLQGMLNISQHQ C  
VKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADAKCTEEDSGS  
NGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI.

Any expressed peptide which substantially corresponds to the MSA1 protein or an immunogenic peptide portion of the MSA1 protein and, preferably, also contains a peptide corresponding to at least an immunogenic portion of the C-terminal MSA1 peptide, may be used in the present vaccines. Of course, expressed peptides corresponding to MSA1 protein and/or an immunogenic peptide portion thereof in combination with a signal sequence or anchor sequence may also be used in the present invention.

The term "signal peptide" "signal sequence" or "signal protein" is used to describe a 7-30 unit amino acid peptide sequence, preferably about a 15-26 unit amino acid peptide sequence, which is generally found at or near the N-terminus of the expressed protein or peptide which is used in the present invention in order to substantially enhance the biological activity of the protein or peptide expressed in the patient according to the present invention. Signal sequences generally contain hydrophobic peptide sequences of between about 7 and 30 amino acid units, more preferably, about 15 to

26 amino acid units, even more preferably about 16 to 24 amino acid units and most preferably about 18 to 20 amino acids units appear to be essential for the targeting of protein chains (generally, secretory proteins) to membranes within the cell. These hydrophobic sequences are of sufficient length to cross the lipid bilayer of the cell membranes. Signal sequences serve as organizers for the cellular traffic of macromolecules. These proteins are believed to play a central role in the translocation of polypeptide chains across membranes. In the present invention, the incorporation of a signal protein sequence at the amino terminus of the protein or peptide sequence expressed by the vaccinated patient is associated with the substantial enhancement in the biological activity (including the therapeutic effect of immunogenicity) associated with the expressed protein or peptide. In the present invention, signal sequences which are known in the art may be used in the present invention. For example, although it may be possible to utilize yeast or lower trophic order signal sequences, clearly mammalian signal sequences are preferred for use in mammals and the specific species signal sequences are most preferred for use in the desired mammalian species to be treated. Thus, in providing for an expressed protein or polypeptide in humans, a human signal sequence is most preferred.

Signal sequences for use in the present invention generally contain three regions, a first or c region at the carboxy end of the peptide (which serves as the cleavage site for a signal peptidase enzyme), comprising about 5 to 7 amino acid residues which tend to be highly polar but uncharged; a second or h region which is N-terminal to the c region, generally about 7 to 13 amino acid residues in length and highly hydrophobic (comprised primarily of Leu, Ala, Met, Val, Ile, Phe, and Trp amino acids, but may contain an occasional Pro, Gly, Ser or Thr amino acid residue); and a third region or n-region of highly variable length and composition, but generally carrying a net positive charge contributed by the N-terminus (negative charges contributed from acidic residues are also known) and any charged residues. Between the c

region and the h region are between 1 and 3 amino acid residues which tend to be small and uncharged (Ala, Gly, Ser, others). Synthetic homopolymeric h regions comprised of amino acids selected from the group consisting of leucine, isoleucine, phenylalanine, valine, alanine and tryptophan, preferably leucine, isoleucine and phenylalanine may be used in the signal proteins according to the present invention. See generally, von Heijne, European Journal of Biochemistry, (1983), 133, pp. 17-21.

The signal sequences which are used in the present invention preferably encompass eukaryotic signal sequences, preferably between 7 and 30 amino acid units in length, preferably between 15 and 26 units, more preferably between about 16 and 26 amino acids, even more preferably between 18 and 20 amino acid units. In the present invention, the c region of the signal peptide should be more polar and the boundary between the h and c regions between residues -5 and -6, or -7 or -8 (counting from the position of cleavage of the signal sequence- i.e., the first amino acid of the mature or expressed protein or peptide is +1) is between 1 and 3 amino acid residues which tend to be small and uncharged (Ala, Gly, Ser, others). Position preferences in the h/c for amino acids are as follows:

-10 most preferably leucine or alternatively, isoleucine, valine, alanine, or phenylalanine;

-9 most preferably leucine, alternatively, isoleucine, alanine, valine, phenylalanine;

-8 most preferably leucine, alternatively isoleucine, alanine, valine, glycine, phenylalanine;

-7 most preferably alanine, alternatively, leucine, isoleucine, valine, phenylalanine;

-6 most preferably valine, alternatively leucine, valine, isoleucine, phenylalanine, alanine;

-5 most preferably proline, alternatively glycine, alanine, leucine, valine;

-4 most preferably glycine, alternatively proline, leucine, alanine, valine;

-3 most preferably alanine, alternatively valine;

-2 most preferably leucine, alternatively phenylalanine;

-1 most preferably alanine, alternatively glycine.

In the signal sequences used in the present invention, the h region may vary in length as well. The n region is polar, contains positively charged amino acids (predominantly lysine and arginine) and varies with the overall length of the signal peptide as described above. The c region extends from residues -1 to -5 of the signal peptide/expressed or mature protein. In terms of location of the c, h and n regions, the c region is N-terminus to the expressed or mature protein, the h region is N-terminus to c region (with a 1-3 amino acid boundary between the c and h region) and the n region is a positively charged N-terminus to the h region. In sum, the n region is variable in length and generally positively charged (with a preferred charge of +2), the h region is hydrophobic and variable in length and the c region preferably contains about five (5-7) generally polar amino acids.

The end of the hydrophobic domain (i.e., the boundary between the hydrophobic residues enumerated above) should preferably be at positions -6/-5. Overall, the signal sequence should comprise a 5 to 10 unit residue initial sequence (beginning with methionine) followed by at least a seven residue sequence (as described above) and an additional amino acids from 1 to 10 residues in length. A typical sequence for the region noted about is:

ILLLLAV.

The signal sequence used should be characteristic of the cell type used for expression of the protein. Thus, in veterinary applications, the signal sequence most preferably used should be that of the animal to be treated. Often a signal sequence which is mammalian in character is acceptable. Most mammalian signal sequences will have significant efficacy in expressing proteins or peptides in other mammalian cells. Human signal sequences are preferably used for human applications.

In the present invention, the following signal peptide DNA sequences are preferably used:

ATG AAGATCATAT TCTTTTATG TTCATTTCTT TTTTATTATA TAAATACACA  
ATGTG; and

ATG AAGATCATAT TCTTTTATG TTCATTTCTT TTTTATTATA TAAATACACA  
ATGTGTAACA CATGAAAGTT ATCAAGAACT TGTCAAAAAA CTAGAAGCTT  
TAGAAGATGC AGTATTGACA GGTATAGTT TATTTCAAAA GGAAAAAATG  
GTATTAAATG AA.

The amino acid sequences corresponding to the above-described signal peptide DNA sequences are:

MKIIFFLCSFLFFIINTQC; and

MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMLNE.

The term "anchor protein" or "anchor peptide sequence" is used to describe proteins or peptides which are anchored to the external surface of the plasma membrane generally by covalent bonding to glycans containing phosphatidyl inositol. These structures to which the anchor protein or peptide is bonded are often referred to as glycosyl phosphatidylinositols or GPIs. In all cells, anchor proteins covalently bonded to GPIs are found on the external face of the plasma membrane of cells or on the luminal surface of secretory vesicles.

In the present invention an "anchor protein" or "anchor peptide" comprises a peptide sequence preferably of about 15-35 residues in length which is generally expressed at the carboxy-terminus of the protein or peptide expressed by the expression vector according to the present invention (3' end of the DNA sequence expressing the desired protein or peptide and carboxyl terminus of the expressed protein or peptide).

In the present invention, many of the proteins or peptides which are expressed in the patient and in particular, the immunogenic proteins or peptides of vaccines according to the present invention which are expressed in the patients produce a biological or immunogenic response in the patient which is substantially enhanced when an anchor peptide is incorporated at the carboxy terminus of that protein or peptide. The inclusion of a signal protein at or in the proximity of the N-terminus, in addition to the anchor peptide at the carboxy-terminus of the expressed protein, is associated with an unexpected enhancement in the biological effects of the expressed protein. This is especially true where the expressed protein is antigenic or immunogenic in nature.

The carboxy-terminus of the expressed protein or peptide residue is modified by attachment of a glycolipid anchor, which serves to anchor the modified protein or peptide to the cell surface. The peptide residue to which the GPI anchor is added is always one of small amino acids, such as glycine, aspartic acid, asparagine, alanine, serine and cysteine. These occur at the carboxyl terminus of the protein/peptide of interest and thus can be specified by inclusion of the appropriate codons in the DNA fragment to be added to the cDNA sequence specifying the protein/peptide of interest. In addition, the two residues downstream of the anchor addition site are usually small.

The cleavage/anchor addition site resides in a domain of three small amino acid residues, although the central of

the three residues has less stringent steric requirements. In order to be certain that functionally or immunologically important amino acids at or near the carboxyl terminus of the protein/peptide target are not compromised, several additional amino acids (preferably, polar ones such as lysine or arginine as well as threonine, alanine and proline) to make up a total of up to 10 residues are inserted in such an orientation so that the small, polar segment is at the carboxyl terminus. The remainder of the addition signal sequence will contain from 15 to 35 amino acids with a hydrophobic domain at the extreme carboxyl terminus. This domain should extend for 15-25 amino acids and will include amino acids such as valine, leucine, isoleucine, alanine, pphenylalanine, but may also contain proline and glycine as well as tryptophan. A typical such sequence is as follows:

TACDLAPPAGTTD **AAHPGRSVVPALLPLL**AGTLLLLLETATAP

The small sequence is in bold face with the left portion representing the terminus of the protein and the D residue the site of GPI addition. The right hand portion is that cleaved during GPI addition with the underlined sequence indicating the hydrophobic terminus.

In the present invention, the anchor peptide may have a cleavable N-terminal sequence, which directs the peptide to the endoplasmic reticulum and the cellular trafficking pathway where the GPI anchor is added. As described above, the anchor peptide also has a predominantly hydrophobic sequence at the extreme carboxy terminus which generally ranges in size from about 15 to about 35, more preferably about 15 to 30, and even more preferably about 15 to 25 amino acid residues, signals the addition of the GPI anchor and is cleaved off concurrent with GPI addition. It is the hydrophobicity rather than the sequence itself which is important for anchor addition. Essentially any hydrophobic amino acid sequence of at least about 15 to about 35, more preferably about 15 to 30 amino acid residues would be capable of directing the addition of a GPI anchor. Anchor addition is generally a transamidation

reaction in which the free ethanolamine amino group of the GPI precursor attacks (by way of nucleophilic addition) a peptide bond at the target amino acid, which becomes the C-terminal amino acid.

Generally, in the expressed anchor peptide sequence, just upstream of the hydrophobic sequence to which the GPI anchor is added is a hydrophilic spacer (usually about 5-10 residues) which contains hydrophilic amino acids. The residue to which the GPI anchor is added (the "anchor addition site") is an amino acid residue within this hydrophilic spacer selected from the group consisting of glycine, aspartic acid, arginine, asparagine, alanine, serine and cysteine. In addition, the two residues downstream from the anchor addition site are also usually small amino acid residues apparently to minimize steric hindrance at the anchor addition site.

Preferably, the GPI portion is preassembled and added as a single unit to a specific amino acid residue near the carboxyl terminus of the expressed protein or peptide. Thus, the carboxyl terminal region may be characterized by the presence of a C-terminal signal peptide which is preferably ten to thirty amino acids in length and provides the information needed to add the GPI anchor. The actual amino acid residue to which the GPI structure is attached is called the omega site and this residue should be glycine, alanine, cysteine, serine, asparagine or aspartic acid. The omega +1 site (towards the carboxyl terminus of the expressed, unprocessed protein) preferably is selected from glycine, alanine, cysteine, serine, asparagine, aspartic acid, glutamate and threonine. The omega +2 site is alanine or glycine. The omega +2 site is followed by a hinge or spacer of ideally 5 to 7 amino acids that preferably contains charged amino acids and proline; this is followed in turn by a preferably hydrophobic sequence of amino acids which terminate the carboxyl signal peptide.

The overall structure of the anchor peptide may be summarized as a 15-35 amino acid peptide at the carboxyl



terminus of the expressed protein or peptide. This anchor peptide sequence (reading from the terminus towards the amino end) begins with a hydrophobic stretch of amino acids of variable length, followed by a sequence of preferably 5-7 amino acids which contains charged residues, followed by three amino acids (either glycine or alanine at the omega +2 site); any of glycine, alanine, cysteine, serine, asparagine, aspartic acid, glutamate and threonine at the +1 omega site; and any of glycine, alanine, serine, cysteine, aspartic acid or asparagine at the omega site.

It is noted that in the present invention, while the signal peptide sequence is generally found at the N-terminus (directly at the N-terminus or removed as much as 1,000 or more amino acids from the N-terminus) and the anchor peptide sequence is generally found at the carboxy-terminus of the expressed protein or peptide, the signal peptide may be found at or near the carboxy terminus of the expressed target protein or peptide.

In the present invention, anchor sequences which are known in the art may be used in the present invention. For example, although it may be possible to utilize yeast or lower trophic order anchor sequences, clearly mammalian anchor sequences are preferred for use in mammals and the specific species signal sequences are most preferred for use in the desired mammalian species to be treated. Thus, in providing for an expressed protein or polypeptide in humans, a human anchor sequence is most preferred.

In the present invention, the following anchor peptide DNA sequence is preferably used:

TTCTTAGGAA TATCATTCTT ATTAATACTC ATGTTAATAT TATCCAGTTT  
CATTTAA.

The amino acid sequence corresponding to the above-described anchor peptide DNA sequence is:

FLGISFLLILMLILYSFI.

In experiments which evidence the utility of the broader invention, the sequences which appear in Figures 2-5 were incorporated into vaccinia virus and were expressed in experimental animals.

It is noted that in the present invention, while the signal peptide sequence is generally found at the N-terminus (directly at the N-terminus or somewhat removed- by as much as 1,000 or more amino acids from the N-terminus) and the anchor peptide sequence is generally found at or in the proximity of the carboxy-terminus of the expressed protein or peptide, the signal peptide may be found at or near the carboxy terminus and the anchor peptide may be found at or near the N-terminus of the expressed target protein or peptide.

The term "effective amount" refers to an amount or concentration of recombinant vaccinia virus effective to produce a protective immune or therapeutic response with respect to the disease malaria. In general, an effective amount of vaccinia virus which is administered to a human patient will vary depending upon a number of factors associated with that patient, including whether the patient previously has been exposed to Plasmodium falciparum before. An effective amount of vaccinia virus can be determined by varying the dosage of the product and measuring the resulting cellular and humoral immune and/or therapeutic responses, prior to administration. In general terms, in humans, this amount represents approximately  $10^4$  to about  $10^7$  plaque forming units, preferably about  $1 \times 10^6$  to about  $5 \times 10^6$  plaque-forming units (determined by assay, as described herein). It is noted that the above described range of administered vaccinia virus is chosen to enhance the likelihood of eliciting an immunogenic response without causing a malaria infection in the vaccine recipient.

In the case where the chimeric peptide is administered instead of the expression vector in order to facilitate an immunogenic response, the amount of chimeric peptide

administered will be an amount or concentration of the peptide to produce a protective immune or therapeutic response with respect to the disease malaria. While this amount may vary over a considerably wide range, depending upon the immunogenicity of the chimeric peptide chosen, generally the amount of peptide administered ranges from about 0.01 micrograms (10 nanograms) to about 250 micrograms, more preferably about 0.1 microgram to about 100 micrograms, even more preferably about 1 microgram to about 25 micrograms within this range.

The present invention contemplates, as a preferred embodiment, the incorporation of both a signal peptide and anchor peptide along with the MSA1 peptide into the expressed peptide has been found to be particularly advantageous in producing an immunogenic response to the MSA1 peptide. The signal peptide sequence is generally incorporated into the immunogenic peptide at or near the amino end of the MSA1 peptide or related antigenic peptide and the anchor peptide is generally incorporated at or near the carboxyl end of the MSA1 peptide. The immunogenic peptide is expressed by the vaccinia virus accordingly and will contain a signal peptide sequence and/or an anchor peptide sequence. Thus, in the present invention, the signal and anchor peptides are preferably expressed at the amino and carboxy terminus of the expressed MSA1 peptide, respectively. Generally, the signal peptide sequence is located upstream from the MSA1 peptide and the anchor peptide is downstream from the MSA1 peptide.

In the method of preparing vaccinia virus which leads to expression of MSA1 peptide, preferably MSA1 peptide containing a signal and/or anchor peptide, by the vaccine recipient, any method which is capable of incorporating a sequence of DNA containing genetic material for the expression of the MSA1 peptide and optionally, a signal peptide and/or an anchor peptide, may be used. The method which is used in the present invention is well known in the art. Accordingly, in the present invention, a DNA sequence containing the genetic code for the MSA1 peptide to be expressed is obtained by

chemical synthesis or other means such as biochemical isolation of available MSA1 DNA sequences and incorporated into a cloning plasmid (for example following cloning vectors: pBR322, pGEM3z, pSP70, pSE420, pRSET, lambdaZAP, all commercially available, among numerous others). The appropriate DNA sequence is cloned, isolated, for example, using agarose gel electrophoresis and then incorporated into an amplification vector and amplified by a standard polymerase chain reaction technique for a sufficient number of cycles to obtain a desired quantity of DNA (depending upon the amount of DNA desired, from about 5 cycles to about 40 cycles or more). A signal peptide sequence and/or anchor peptide sequence may be incorporated into a vector containing the MSA1 peptide and, after identification (selection and screening) of the appropriate DNA fragments in positive clones by PCR and endonuclease digestion, amplified accordingly using the same techniques.

After amplification, the DNA is incorporated into a transfer vector and transfected with eukaryotic cells, for example, monkey kidney cells (BSC-1 cells), and with wild-type vaccinia virus (WR) to produce recombinant vaccinia virus. The recombinant vaccinia virus is then purified before amplification. After amplification and in some cases further purification, the recombinant vaccinia virus is then administered to an animal as an immunogenic dosage form which expresses MSA1 peptide or an immunogenic portion thereof, preferably, in combination with a signal peptide and/or an anchor peptide.

Alternatively, once a nucleic acid sequence encoding immunogenic chimeric protein is present in a suitable expression vector, the expression vector may be used for the purpose of expressing the immunogenic chimeric protein in a suitable eukaryotic cell system, for example, to promote the production of the desired peptide sequence outside of the host animal. Such eukaryotic cell systems include, for example, HeLa, L929, T2 or RMA-2, preferably T2 or RMA-S. In this method, the cells which contain the expression vector(s) are grown and

then lysed in order to isolate synthetic peptides which contain the desired protein or peptide sequence in combination with the anchor peptide sequence and/or the signal sequence. The isolated peptide sequence may then be used directly as a therapeutic or immunogenic dosage form. Alternatively and preferably, the expression vector may be administered directly to the patient where it will express the desired protein or peptide and anchor sequence and render the intended therapeutic or immunogenic effect on the patient.

The expressed protein may be obtained from cell culture after the cells are lysed by standard protein purification procedures known in the art which may include, among others, gel electrophoresis, affinity and immunoaffinity chromatography, differential precipitation, molecular sieve chromatography, isoelectric focusing and ion-exchange chromatography. In the case of immunoaffinity chromatography, the protein or peptide may be purified by passage through a column containing a resin to which is bound antibodies which are specific for at least a portion of the protein or peptide.

The expressed protein or peptide containing a signal peptide sequence and/or an anchor peptide sequence, which is obtained from cell culture, may be administered in pure or substantially pure form to a patient in need of such therapy by purifying the crude lysate from cell culture. Preferably, the expressed protein is administered in pharmaceutical dosage form as a composition or formulation comprising an immunogenically effective amount of the expressed protein containing anchor peptide sequence and/or signal peptide sequence, in combination with a pharmaceutically acceptable additive, carrier or excipient. The formulations may be delivered in unit dosage form prepared by known methods in the art. The amount of expressed protein or peptide administered will vary depending upon the pharmacokinetic parameters, severity of the disease treated or immunogenic response desired. Of course, dosages will be set by the prescribing physician considering relevant factors including the age, weight and condition of the patient including, in the case of immunogenic dosage forms, whether

the patient has been previously exposed to the microorganism responsible for the disease to be vaccinated against as well as the release characteristics of the expressed protein from pharmaceutical dosage forms of the present invention.

The amount of the expressed protein which is administered according to the present invention comprises an amount effective to produce the intended effect, i.e., to obtain an immunogenic response in the patient which provides a substantially protective effect against malaria.

Alternatively and preferably, the vaccine which is administered according to the present invention comprises an amount of an expression vector, preferably, a recombinant vaccinia virus effective to express sufficient MSA1 peptide to provide an immunogenic response in a patient. Preferably, the MSA1 peptide or an immunogenic peptide sequence thereof is combined with a signal and/or anchor peptide to substantially increase the immunogenicity of the expressed MSA1 peptide compared to MSA1 peptide which does not contain a signal and/or anchor peptide. The immunogenic response provides a protective effect against the merozoite stage of malaria.

The present vaccine can be injected as is, or for convenience of administration, can be added to a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers will be apparent to those skilled in the art, and include water and other polar substances, including lower molecular weight alkanols, polyalkanols such as ethylene glycol, polyethylene glycol, and propylene glycol as well as non-polar carriers.

Dosages of recombinant vaccinia virus or chimeric protein or peptide according to the present invention which are coadministered with carriers will often be about the same as the amount administered alone (in the absence of coadministration). Of course, dosages will be set by the prescribing physician considering relevant factors including the age, weight and condition of the patient including whether the

patient has been previously exposed to Plasmodium falciparum and the release characteristics of the vaccinia virus from pharmaceutical dosage forms of the present invention.

In the malaria vaccine aspect of the present invention, the dose of vaccinia virus will depend upon the form in which it is administered. For example, the vaccine will generally contain a concentration of virus ranging from about  $10^4$  to about  $10^7$  plaque forming units, preferably about  $1 \times 10^6$  to about  $5 \times 10^6$  plaque-forming units, depending upon the desired levels of expressed immunogenic protein. Thus, the concentration or amount of vaccinia virus included within the present vaccine will generally fall within this range; however, the amount of recombinant vaccinia virus used in any vaccine form will depend upon the strength of the immunogenic response elicited.

In determining the amount of vaccinia virus in a given vaccine dose, the following method may be used. In certain vaccine dosage forms, standard pharmaceutical carriers as described above may be included. The ratio of virus included in the vaccine will depend on the chemical nature, solubility, and stability of the virus, as well as the dosage contemplated. For parenteral administration or injection via such parenteral routes as intraperitoneal, intramuscular, subcutaneous, intramammary or other route, sterile solutions of the vaccinia virus are prepared. Vaccines according to the present invention may also be administered intravenously. Preferably, the vaccines according to the present invention are administered via a subcutaneous route.

The dosage of the vaccine employed and the treatment schedule would follow practices normally employed for other vaccination or therapeutic regimens wherein this general method of treatment is employed. It is not anticipated that more than one dose of vaccine initially would be required, but the possibility of providing booster doses is anticipated. Preferably, the dosage schedule for immunization against malaria involves the subcutaneous injection of at least about

$1 \times 10^6$  plaque-forming units of vaccinia virus.

In the immunogenic method according to the present invention, a human patient is administered with an effective amount of vaccinia virus such that expressing the MSA1 peptide or an immunogenic peptide thereof, preferably in combination with a signal and/or anchor peptide. Alternatively, an immunologically effective chimeric peptide comprising the MSA1 peptide or an immunogenic portion thereof in combination with a signal peptide and/or anchor peptide will be administered. In certain instances, an additional boost of vaccinia virus or peptide may be given to promote the immunogenic response. Additional doses of vaccine may be provided to boost the initial inoculation, if needed.

The following examples are provided for purposes of illustration only and are not to be viewed as a limitation of the scope of the invention.

### EXAMPLES

#### Methods and Materials

##### Virus and cells

Monolayer cultures of monkey kidney cells (BSC-1) and Hu134TK-cells were grown in Dulbecco's modified Eagle's medium (D-MEM) supplemented with 10% fetal bovine serum (FBS). Monolayer cultures of Hela cells and CV- cells were grown in Dulbecco's modified Eagle's medium (D-MEM) supplemented with 10% FBS.

Wild type vaccinia virus Western Reserve (WR) was grown in BSC-1 cells.

##### In vitro culture of *P. falciparum*

*P. falciparum* isolates (FCR-3, a strain identical to the Wellcome strain sequenced by Holder, et al., Nature, 1985,



317, 270-273) were maintained in human erythrocytes in RPMI 1640 medium supplemented with 25 mM Hepes, 32mM sodium bicarbonate and 10% human serum in a 5% O<sub>2</sub>, 5% CO<sub>2</sub>, 90% N<sub>2</sub> environment at 37°C. *P. falciparum* strain FCR-3 was kindly donated by Dr. Isabella Quakyi, Georgetown University, Washington, D.C.

#### Preparation of antisera to C-terminal of MSA1

pME-2 is an expression plasmid derived from pWRL507, in which the C-terminal of the MSA1 gene (3555-5917bp, Wellcome Allele of MSA1) was inserted at the 3' end of a truncated *trpE* gene, so that expression was controlled by the *trp* promoter. The protein was expressed using the method described by Holder, et al., *Parasite Immunol.*, 1988, 10, 607. The fusion protein expressed was insoluble. DH5alpha competent cells (GIBCO BRL) were transformed by pME-2, and a 1ml culture of a pME-2 positive clone was inoculated into 100ml M9 medium containing 100 ug/ml (micrograms per ml) Amp and grown overnight. This overnight culture was added to 400ml M9 containing 100 ug/ml Amp and 10 ug/ml indoleacrylic acid, and after 5 hr. growth at 37°C and 250 rpm, the cells were harvested. The pellet was then rinsed in 10 ml PBS and frozen to -20°C. The cell pellet was thawed in a 10ml solution containing 25 mM Tris pH 8.0, 1mM EDTA, 0.2% NP-40 and 100 ul 100mM PMSF.

When the pellet was fully resuspended, lysozyme was added to a final concentration of 1mg/ml, and the solution was placed on ice for 2 hrs. After this time, 20 ul 1M MgSO<sub>4</sub>, and 20ul 10 mg/ml DNase were added, and the solution was again left to incubate on ice for 2 hrs. After 10 min. centrifugation at 13000 rpm, the pellet was rinsed in 10 ml of washing buffer (50 mM Tris, 5 mM EDTA, 5 mM EDGA, 1% NP-40 containing 100 ul 100 mM pMSF). The material was centrifuged as above to yield a further pellet and this pellet was resuspended in a 10 ml solution of 0.5M KSCN, 50mM tris, 5mM EDTA and 5mM EGTA and re-centrifuged as above. Finally, the pellet was resuspended in 3 ml water. The product was analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the gel containing the 105 kD protein of interest was then cut into approximately 1-5 mm<sup>2</sup>

pieces. The fusion protein was eluted with a Bio-Rad Model 422 Electro-Eluter, and the vacuum-dried product was dissolved in PBS. The concentration was assayed with a BCA protein Assay Reagent Kit (PIERCE). Antiserum to the fusion protein was prepared by immunizing Balb/c mice intraperitoneally on two occasions 21 days apart with 100 ug of protein in the presence of Titre-Max (Vaxcel, Inc.). Antiserum was collected 10 days after the second immunization.

#### Plasmid Construction

##### (1) Amplification of MSA1 signal sequence (Si)

pGEX-2T-P190CR1 (pGEX-2T containing the MSA1 gene from 1 to 150bp) was used as a sample in PCR. The 100ul mixture contained 100 pmol primer 1 and 100 pmol primer 2 (Table 1, below), 2.5units Ampli Taq DNA polymerase, dNTP and 10ul 10x reaction buffer (PIERCE). The sample was overlaid with several drops of mineral oil to prevent evaporation and subjected to 30 cycles of amplification (94°C melt, 72°C extension, 55°C annealing). Amplified products were identified on a 1.5% agarose gel.

**Table 1**  
**Relative Positions of Amplified Gene Fragments From PF**  
**MSA1 and Primer Sequences**

Amplified Gene Fragments	Relative Position in MSA1 Gene <sup>a</sup>	Primer	Primer Sequence
Fragment Containing Signal Sequence	418-582	1	GC <u>GTCGAC</u> ATG AAG ATC ATA TTC TTT TTA SaII
		2	GC <u>GAATTCAA</u> TTC ATT TAA TAC CAT TTT TTC EcoRI
MSA1C-A	3556-5337	3	GC <u>GAATTC</u> ACT TAA TAA CCC AAA GCA TGT EcoRI
		4	GC <u>GGTACC</u> TTA AAT GAA ACT GTA TAA TAT KpnI
MSA1C-Si, nA	418-582 3553-5280	1	GC <u>GTCGAC</u> ATG AAG ATC ATA TTC TTT TTA SaII
		5	GC <u>GGTACC</u> TTA GTT AGA GGA ACT GAC GAA AAT KpnI
MSA1C-nSi, nA	475-582 3553-5280	6	GC <u>GTCGAC</u> ATG GTA ACA CAT GAA AGT TAT CAA SaII
		5	GC <u>GGTACC</u> TTA GTT AGA GGA ACT GAC GAA AAT KpnI
MSA1C, nSi, A	475-582 3553-5337	6	GC <u>GTCGAC</u> ATG GTA ACA CAT GAA AGT TAT CAA SaII
		4	GC <u>GGTACC</u> TTA AAT GAA ACT GTA TAA TAT KpnI

<sup>a</sup>GCG, Accession no. X02919. The start codon of MSA1 is at 418.

The MSA1C-(Si, nA), MSA1C-(nSi, nA), MSA1C-(nSi, A) fragments contain the 108bp region directly downstream from the signal sequence and an additional 2bp on the 5' end of the C-terminal to preserve the reading frame. Furthermore, a start codon was also added to the two fragments lacking the start-codon-containing signal sequence, a stop codon was also added to the two fragments lacking the anchor region.

(2) Amplification of C-Terminal of MSA1(MSA1C-A)

pME-2 plasmid was used as a template in PCR. The 100ul (microliter) mixture contained primers 3 and 4 (Tab. 1) and was subjected to 30 cycles of amplification (94°C melt, 72°C

extension, 50°C annealing). The amplified products were identified on a 0.8% agarose gel.

pSPORT1-MSA1C-(Si,A) (Figure 1) was used as a template in PCR. MSA1C-(Si,nA) (primer 1 and primer 5, Tab. 1), MSA1C-(nSi,A) (primer 5 and primer 4), and MSA1C-(nSi,nA) (primer 6 and primer 5) fragments were amplified as well with the above procedures.

### (3) Isolation, purification and cloning of gene fragments

The MSA1C-A fragment was amplified by PCR, and electrophoresis in a 0.8% agarose gel indicated that the amplified fragment was about 1.8kb. This fragment and pSPORT1 were digested with EcoRI and KpnI and were mixed and treated with T4 DNA ligase. The ligation products were transformed into DH5alpha competent cells. X-gal and ampicillin were used to screen the positive clones (pSPORT1-MSA1C-A, Figure 1). Recombinant plasmids were prepared from positive white colonies and identification was performed with SalI and EcoRI digestion. The full sequence of the insert was determined.

The fragment containing the signal sequence was amplified by PCR, and electrophoresis in a 1.5% agarose gel indicated that the size of the amplified fragment was about 180bp. The Si and pSPORT1-MSA1C-A fragments were then digested with SalI and EcoRI, ligated and transformed, and 30 colonies were selected and screened by PCR using primer 1 and primer 2. Recombinant plasmids (pSPORT1-MSA1C-(Si,A), Figure 1) were

identified with SalI and EcoRI digestion and were sequenced, and the correct reading frame was established. pSPORT1-MSA1C-(Si,A) was then used as a template to amplify MSA1C-(Si,nA), MSA1C-(nSi,A) and MSA1C-(nSi,nA).

MSA1C-(Si,nA), MSA1C-(nSi,A), MSA1C-(nSi,nA) digested with SalI and EcoRI and MSA1C-(Si,A) cut from pSPORT1-MSA1C-(Si,A) were inserted separately into the SalI and KpnI sites of pSC65. Positive clones were screened by PCR and SalI and KpnI digestion, the 5' and 3' ends of each insert were sequenced, and the correct reading frame was established.

Figure 1 diagrams the construction of recombinant vaccinia viruses incorporating the sequences corresponding to MSA1C-(Si,A), MSA1C-(Si,nA), MSA1C-(nSi,A) and MSA1C-(nSi,nA). Essentially, the MSA1C-terminal fragment containing the anchor region was inserted into the pSPORT1 plasmid using the marked EcoRI and KpnI sites, creating the pSPORT1-MSA1C-A plasmid. The fragment containing the signal region (FSi) and the 108 bp downstream was PCR amplified with a SALIU site on the 5' end and then inserted into the pSPORT1-MSA1C-A plasmid to produce pSPORT1-MSA1C-(Si,A) plasmid. The entire MSA1C-(Si,A) fragment (from the SalI site to the KpnI site) was then removed and inserted into the pSC65 vector to make the final pSC65-MSA1C-(Si,A) transfer vector. The other three recombinant transfer vectors (pSC65-MSA1C-(nSi,nA), pSC65-MSA1C-(nSi,A) and pSC65-MSA1C-(Si,nA)) were produced by adding the desired SalI or KpnI sites where necessary by PCR amplification. The amplified fragments were then inserted into the pSC65 plasmid.

In all four cases, the insertion site is adjacent to the synthetic early/late promoter (pS-E/L). Tk<sub>L</sub> and TK<sub>R</sub>, right and left regions of the vaccinia virus thymidine kinase gene; LacZ, beta-galactosidase gene.

DNA sequencing

DNA sequencing was performed using the dideoxy nucleotide chain termination method according to the protocols for DNA sequencing with TAQ version 2.0 DNA polymerase (United States Biochem). Figures 2-5 are the DNA (gene) sequences for MSA1C -(Si,A), MSA1C-(Si,nA), MSA1C-(nSi,A) and MSA1C-(nSi,nA).

Transfection and isolation of recombinant vaccinia viruses

Monolayers of BSC-1 cells were grown to 90% confluence in a six-well plate, media was removed, and the cells were infected with wild-type vaccinia virus (WR) at 0.1-1 plaque forming units(pfu)/cell for 1 hour. The virus inoculum was removed, and the monolayer was washed twice with OptiMEM (GIBCO BRL) serum-free medium. 1ml of Opti-MEM was added to the infected monolayers and mixed gently with 50 ul of lipofectin-DNA complex (5 ug of recombinant pSC65 was diluted to 25 ul with sterile distilled water, 15 ug of lipofectin reagent was diluted to 25 ul with sterile distilled water, and the solution was gently mixed in a polystyrene tube and allowed to stand for 15 minutes at room temperature). After 5 hours incubation at 37°C, the medium was replaced with 3 ml E-MEM supplemented with 2% FBS and incubated for another 48 hours. After removal of the medium, cells were harvested by scraping into 1 ml of E-MEM supplemented with 2% FBS. The virus was released by three cycles of freeze-thawing at 37°C. After removal of medium, 1ml of diluted freeze-thawed trans-

fection mixture (sonication 30 seconds at 4°C before adding) was added to monolayers of Hu 134 TK- grown to 90% confluence in a six-well plate, and the virus was left for 1 hour at 37°C. The infected cells were overlaid with E-MEM supplemented with 2% FBS containing 1% low-melting-point agarose and 25 ug/ml of bromodeoxyuridine. Thirty-six hours post-infection, monolayers were overlaid with E-MEM supplemented with 2% FBS containing 1% low-melting-point agarose, 0.02% neutral red and 300 ug/ml X-gal. After the agarose had set, monolayers were incubated for 6-8 hours before plaques were stained and picked (using a sterile glass Pasteur pipette) into 1 ml of diluent and freeze-thawed 3 times. The recombinant products were plaque purified before amplification to produce small virus stocks.

#### Immunostaining of vaccinia recombinant plaques

BSC-1 cells were infected with recombinant vaccinia virus, and the medium was removed from infected tissue-culture plates 24 hours postinfection. The cells were fixed with a 1:1 acetone:methanol mixture for 2 minutes, the wells were washed with 1ml of PBS, and then anti-MSA1C-A serum diluted 1:200 in PBS containing 2% FBS was added to the wells, 1 ml/well. The six-well plate was incubated at room temperature for 1 hour, rocking gently, after which the wells were washed twice with 1 ml of PBS. Anti-mouse-peroxidase diluted 1:1000 in PBS with 2% FBS was added to each well, and the plate was incubated for 45 minutes at room temperature. After washing twice with PBS, 0.5 ml of substrate solution was added (the substrate solution



was made by dissolving a pinch of dianisidine in 500ul of absolute ethanol, vortexing, and warming it for 5-10 minutes, then centrifuging it for 30 seconds and adding 200ul of substrate solution to 10 ml of PBS plus 10ul of 30% H<sub>2</sub>O<sub>2</sub>). The plate was then left for 5-10 minutes at room temperature.

Indirect immunofluorescence staining of recombinant vaccinia-infected cells

HeLa cells were seeded on pre-treated coverslips for 48h, after which the cells were infected at an M.O.I. of 5 in a volume of 0.25 ml of D-MEM with 10% FBS. These were overlaid with 1.5 ml D-MEM with 10% FBS 1-2 h postinfection. The cells were then washed with PBS and fixed for 15 min in 3% paraformaldehyde in PBS. After being washed in PBS, the coverslips were incubated in 50mM ammonium chloride in PBS for 10 min at room temperature. After the slips were again washed in PBS, anti-MSA1C-A serum diluted 1:800 in PBS was added to each well, and they were incubated for 30 min at 4°C. The coverslips were then washed three times in PBS, and the cells were incubated with FITC goat-anti-mouse for 30 min at 4°C. After being washed in PBS, the coverslips were blotted on tissue and mounted on slides in 5% DABCO/Mowiol.

Western blot analysis

Confluent six-well plates of BSC-1 cells were infected with recombinant vaccinia virus in 1 ml medium at an M.O.I of 5. Cells from each well were harvested 24 hours post-infection. After centrifugation at 8000 rpm for 5 min, the

supernatant was concentrated to 10-15 ul with a microcon 30 (Amicon, Inc.), and the cell pellet was resuspended in PBS to a final volume of 200 ul. The same volume of 2x sample buffer (100 mM Tris, 200mM dithiothreitol, 4% SDS, 0.2% bromophenol blue and 20% glycerol) was added, and the resulting solution was boiled for 5 min and loaded in a 8% Tris-glycine-SDS gel. Electrophoresis was performed in Tris-glycine-SDS running buffer, and proteins were transferred to a PVDF membrane by electrophoresis in transfer buffer (25mM Tris-HCl, 192mM glycine, 155 methanol) at 100V for 30 min at 4°C. The blot was blocked with 5% BSA in Tris-HCl (200mM, 0.85%) for 2 h at room temperature before addition of a 1:500 dilution of anti-MSA1C-A serum. After 2 hours incubation the blot was washed three times in Tris-HCl, pH 7.4 for 10 min per wash. A 1:7500 dilution in Tris-HCl, pH 7.4 of alkaline phosphatase-conjugated goat-anti-mouse IgG (Promega) was added, and the blot was incubated for 90 min at room temperature before being washed four times in Tris-HCl, pH 7.4 for 10 min each wash. Western blue stabilized substrate for alkaline phosphatase (Promega) was added, and after about 5 minutes, the blot was washed with water to stop development.

#### Large-scale preparation and plaque titration of vaccinia virus stocks

##### (1) purification of vaccinia viruses

$5 \times 10^7$ - $10^8$  HeLa S3 cells in E-MEM supplemented with 2% FBS were incubated in a 162 cm<sup>2</sup> flask at 37°C for 18 h, after which the cells were infected with small stock viruses at 37°C

for 48 h and pelleted by centrifugation for 5 min at 1800 g. The infected cells were resuspended in 10 mM Tris-HCl, pH 9.0 and homogenized with 30-40 strokes (while still on ice). The mixture was centrifuged for 5 min at 300g to remove nuclei, and the pellet (removed supernatant was kept as well) was resuspended in 10 mM Tris-HCl, pH 9.0 and centrifuged again (supernatants were pooled). The sonicated supernatant was layered onto a cushion of 36% sucrose in a Beckman SW27 centrifuge tube and spun at 35000 rpm for 45 min at 4°C, after which the virus pellet was resuspended in 1 ml of 1mM Tris-HCl, pH 9.0. The wild-type virus was further purified by continuous sucrose gradient centrifugation.

## (2) Plaque titration of vaccinia virus stocks

Monolayers of BSA-1 cells were grown to 95% confluence in a six-well plate, virus stocks were sonicated, and 10 fold serial dilutions ( $10^{-7}$ - $10^{-9}$ ) of the virus in E-MEM supplemented with 2% FBS were made. The BSC-1 cells were infected with 1 ml of virus diluted to  $10^{-7}$ ,  $10^{-8}$  and  $10^{-9}$  in duplicate. After 48 h of incubation, the medium was removed and 0.5 ml of crystal violet solution was added. After another 15 min incubation at room temperature, the plates were washed with water, and the plaques were counted after drying.

## ELISA determination of antibody response

### (1) Antibody responses to MSA1C-A

A ninety-six-well microtiter plate (IMMULON 2, Dynatech Laboratories Inc, VA) was coated with 100 ul/well of a 5 ul/ml solution of MSA1C-A in Tris-NaCl (0.02,0.85%), pH 7.4 and kept overnight at 4°C. The antigen-coated plate was then washed with Tris-NaCl and blocked with 150 ul 1% BSA in Tris-NaCl, pH 7.4 for 2 h at 37°C. After washing with Tris-NaCl, pH 7.4, 100 ul of serial 10-fold dilutions (diluted in Tris-NaCl containing 1% BSA and 0.05% Tween 20) of sera were added to the wells in duplicate. After 2 h incubation at 37°C, the plate was rewashed with Tris-NaCl containing 0.05% Tween 20 and phosphatase-labeled IgG was added. After another 2 h incubation at 37°C, the plate was washed with Tris-NaCl containing 0.05% Tween 20 and developed by adding alkaline phosphatase substrate in diethanolamine buffer, pH 9.8. The plate was scanned in a Dynatech ELISA scanner at 405 nm.

(2) Antibody responses to vaccinia virus

Purified WR vaccinia virus was diluted in Tris-NaCl, pH 7.4 to a final concentration of approximately  $5 \times 10^6$  pfu/ml and 100 ul volumes were dispensed into the wells of a 96-well plate (IMMULON 2, Dynatech Laboratories Inc) and left for 2 h at 37°C. The buffer was removed and virus was inactivated with 50 ul of 10% paraformaldehyde for 10 min at 4°C. The plates were then blocked just as those in the first group and developed using the procedure described above.

Indirect fluorescent-antibody tests for parasite

*P. falciparum* parasites were cultured in human erythrocytes to a parasitemia of 8% at the schizont stage, at which point they were washed five times in PBS (10x volume). Small samples were then taken, smeared on a glass slide and fixed in cold methanol. After being washed in PBS, the samples were probed with antiserum from mice immunized with the recombinant and wild-type viruses. After this probe, the samples were probed with FITC goat-anti-mouse antibody and mounted in 5% DABCO/ Mowiol.

#### In vitro invasion assay

Preparation of samples: Rabbit pre-immune serum or anti-serum (6.7ml) was heat-inactivated at 56°C for 25 minutes, and antibodies in the absorbed serum were precipitated with ammonium sulfate. After centrifugation, the pellets were dissolved in a minimal volume of PBS, then dialyzed overnight three times in PBS. Finally, the volume was adjusted to 1 ml.

*P. falciparum* parasites were synchronized twice with 5% sorbitol (Diana), and after 24 hours a mixture of trophozoites and schizonts at 3% parasitemia and 3% hematocrit was transferred to 96-well culture plates (170ul/well). Anti-serum, pre-immune serum or serum-free medium was added to the parasites in a volume of 30 ul to make a final volume of 200ul/well, and the plates were incubated at 37°C in an air-tight chamber equilibrated for 5 min with 5% O<sub>2</sub>, 5% CO<sub>2</sub> and 90% N<sub>2</sub>. After 22-24 hours, cell morphology was verified to

make sure that all schizonts had burst. Once this was verified, 4ul of homogenized infected red blood cells from each well were fixed in 2 ml 0.01% (w/v) glutaraldehyde for 45 min at room temperature. After fixing, the cells were centrifuged at 1500 rpm at 4°C for 10 min and then stained with 50ug/ml propidium iodide overnight at 4°C in darkness. Total parasitemia was determined by counting fluorescent cells using a fluorescence-activated cell sorter. 20000 cells were counted from each sample. The percentage inhibition of invasion during the 22-24 hour period was determined by the following formula:

$$\% \text{ inhibition} = \frac{(\text{pre} - 0 \text{ hr}) - (\text{T} - 0 \text{ hr})}{(\text{pre} - 0 \text{ hr})} \times 100\%$$

Here, "T" is the parasitemia of tested serum, "pre" is the parasitemia of preimmune serum and "0 hr" is the starting parasitemia.

## Results

### Construction of recombinant vaccinia virus

The construction of the recombinant vaccinia virus is described in Figure 1. Four recombinant vaccinia virus transfer plasmids were made: pSC65-MSA1C-(Si,A), which is recombinant pSC65 in which the MSA1 peptide containing the signal and anchor regions of MSA1 has been inserted into the SalI and KpnI site; pSC65-MSA1C-(Si,nA) (the same except the MSA1 contains the signal without the anchor); pSC65-MSA1C-(nSi,A) (the same except the MSA1 contains the anchor without the signal) and pSC65-MSA1C-(nSi,nA) (the same except the MSA1 contains neither the signal nor the anchor).

The vaccinia virus transfer vector, pSC65, has a synthetic compound early/late promotor (pSE/L) so that the foreign genes controlled by the promotor are expressed throughout the virus growth cycle. The SalI, BglII, StuI, AatI, KpnI, SmaI, XmaI and PacI sites are located just downstream of the pSE/L for insertion of a foreign gene, and there are E. coli beta-galactosidase gene sequences (controlled by the p7.5 vaccinia virus promotor which has early and late vaccinia virus transcriptional regulatory signals) and vaccinia TK gene sequences flanking the entire pSE/ L and foreign gene region to direct homologous recombination into the TK locus of the vaccinia virus genome.

BSC-1 cells were infected with wild-type (WR) vaccinia

virus and then were transfected with recombinant pSC65. Serial dilutions of progeny virus were then applied to monolayers of Hu 134 TK- cells in the presence of BrdU to select TK- recombinant virus plaques. These were then distinguished from spontaneous TK- mutants by addition of X-gal to the low-melting-point agar overlay. Plaques that stained blue due to expression of beta-galactosidase were picked and then plaque-purified a second time prior to preparation of virus stocks. The four recombinant vaccinia viruses were named as rV.V-MSA1C(Si,A); rV.V-MSA1C-(Si,nA); rV.V-MSA1C-(nSi,A) and rV.V-MSA1C(nSi,nA) (Figure 6).

Expression of MSA1C-(Si,A), MSA1C-(Si,nA), MSA1C-(nSi,A) and MSA1C-(nSi,nA)

(1) Immunostaining of vaccinia recombinant plaques

BSC-1 cells were infected with rV.V-N,ISA1C-(Si,A), rV.V-MSA1C(Si,nA), rV.V-MSA1C-(nSi,A) and rV.V-MSA1C-(nSi,nA), and the infected cells were fixed with acetone/methanol 24 hours post-infection, after which the expressed proteins were labeled by anti-mouse-peroxidase. The results indicated that the cells infected by the recombinant vaccinia virus expressed the C-terminal protein.

(2) Western blot analysis of recombinant vaccinia virus expressed proteins

BSC-1 cells were infected with rV.V-MSA1C-(Si,A),



rV.V-MSA1C(Si,nA), rV.V-MSA1C-(nSi,A), rV.V-MSA1C-(nSi,nA) and WR viruses. These cells were then harvested 24 hours post-infection, and the cell pellets and 50-times concentrated supernatants were run on an 8% Tris-glycine-SDS gel. The blot was labeled with anti-MSA1C-A mouse serum and then probed by alkaline phosphatase-conjugated goat anti-mouse IgG. The results indicated that the infected cells expressed the C-terminal region of MSA1, and that the molecular weights of MSA1C-(Si,nA), MSA1C-(nSi,A) and MSA1C(nSi,nA) were about 70kD, and MSA1C-(Si,A) was about 60kD. Furthermore, none of the four expressed proteins appeared to be secreted by the cells. Figure 7 shows a Western blot analysis, using the anti-MSA1C-A mouse serum as a probe, of proteins expressed from BSC-1 cells infected with vaccinia virus.

### (3) Indirect immunofluorescence

Immunofluorescence microscopy of cells on coverslips demonstrated that MSA1C-(Si,A) and MSA1C-(Si,nA) were expressed on the surface of infected cells, and that MSA1C-(nSi,A) and MSA1C-(nSi,nA) were not expressed on the surface of infected cells. Therefore, we have concluded that the signal region is vital for the expression of the protein on the cell surface. Figure 8 shows indirect immunofluorescence staining of recombinant vaccinia-infected cells.

### (4) Antibody response in rabbits

Five rabbits were inoculated intradermally with rV.V-

MSA1C-(Si,A); rV.V-MSA1C-(Si,nA); rV.V-MSA1C-(nSi,nA); rV.V-MSA1C-(nSi,A) and WR on days 0, 21, 47 and 68. The ELISA titers of rV.V-MSA1C-(Si,A) and rV.VMSA1C-(Si,nA) were 5-10 times greater than that of rV.V-MSA1C-(nSi,nA) and rV.V-MSA1C-(nSi,A) after the fourth inoculation. One rabbit was inoculated intravenously on day 0 with rV.V-MSA1C-(Si,A) and reinoculated on days 47 and 68, and the ELISA titer of i.v. rV.V-MSA1C-(Si,A) was 5 times that of i.d. rV.V-MSA1C-(Si,A). Also, the ELISA titer of i.v. rV.V-MSA1C-SiA decreased suddenly after the third inoculation, possibly because the antibody neutralized the virus. The data show that rV.V-MSA1C-(Si,A) and rV.VMSA1C-(Si,nA) can induce significantly stronger antibody responses against MSA1C-A in rabbits than rV.V-MSA1C-(nSi,nA) and rV.V-MSA1C-(nSi,A), and that rV.V-MSA1C-(Si,A) can induce quicker antibody response after a second inoculation when introduced intravenously than when introduced intradermally (Figure 9).

#### (5) Antibody response in mice

Five groups of Balb/c were inoculated i.p. with  $1.0 \times 10^8$  rV.V-MSA1C(Si,A), rV.V-MSA1C-(Si,nA), rV.V-MSA1C-(nSi,nA), rV.V-MSA1C-(nSi,A) and WR. rV.V-MSA1C-(Si,A) and rV.V-MSA1C-(Si,nA) stimulated a level of the C-terminal-specific antibodies that was 5-10-fold greater than the level induced by rV.V-MSA1C-(nSi,nA) and rV.V-MSA1C-(nSi,A) after the third inoculation. The ELISA titer of rV.V-MSA1C-(Si,A) was about 1:10000 and lasted about 3 months (Figure 10).

Wild type (WR) vaccinia virus coated on a 96-well plate was probed with a serial 10-fold dilution of mouse antibodies raised against rV.V-MSA1C-(Si,A), rV.V-MSA1C-(Si,nA), rV.V-MSA1C-(nSi,nA), rV.V-MSA1C(nSi,A) and WR, and then probed by alkaline phosphatase-labeled goat antimouse IgG. The results showed that the anti-WR virus antibody titers of the recombinant and the WR viruses were almost the same after the second inoculation. Therefore, it appears that all of the mice immunized with the recombinant and WR viruses were successfully infected by the viruses (Figure 10). CBA/J mice were also immunized with rV.V-MSA1C-(Si,A), rV.V-MSA1C-(Si,nA), rV.V-MSA1C-(nSi,nA), rV.V-MSA1C-(nSi,A) and WR viruses. The resulting antibody titers were similar to those of the Balb/c mice although slightly lower (data not shown).

These results indicated that the cell-surface expression of the C-terminal region and the combination of the C-terminal region and the signal and anchor peptides of MSA1 are important in the stimulation of the C-terminal-specific antibody response in rabbits and mice.

rV.V-MSA1C-(Si,A)-induced mouse antibody recognized 190kD protein of parasite in Western blot

Schizont stage parasites resuspended in 1x sample buffer were boiled for 5 minutes and loaded onto a 4-20% Tris-glycine gradient gel, and the proteins were transferred to a PVDF membrane by electrophoresis. The blots were then probed by anti-MSA1C-(Si,A) and anti-MSA1C-A and labeled by alkaline phosphatase-conjugated goat anti-mouse IgG. The 190kD protein

was recognized by anti-MSA1C-A in a Western blot, so we have concluded that the 190kD protein is MSA1. Anti-MSA1C-(Si,A) recognized the 190kD protein (MSA1) as well. (Figure 11) The data demonstrate therefore that the recombinant vaccinia virus correctly expresses the MSA1 fragment in mice.

#### Indirect immunofluorescence test for parasite

Human erythrocytes infected with the *P. falciparum* parasite were probed with differing dilutions of the antisera produced by the mice immunized with the four recombinant viruses and the wildtype virus. MSA1C-(Si,nA) and MSA1C-(Si,A) were both positive at a dilution of 1:16, and MSA1C-(Si,A) remained positive at 1:128, while MSA1C-(nSi,nA) and MSA1C-(nSi,A) were both negative at 1:16, as compared to the WR negative control (data not shown).

#### Invasion Assay

Table 2. Inhibition of *P. falciparum* invasion of human erythrocytes by antisera ( $\bar{x} \pm s.\%$ )

<u>Antisera</u>	<u>Antiserum dilution in culture</u>			
	<u>undiluted</u>	<u>1:10</u>	<u>1:100</u>	<u>1:1000</u>
MSA1C-(Si,nA)	54.6 $\pm$ 6.7	46.2 $\pm$ 9.4	30.9 $\pm$ 10.8	28.9 $\pm$ 9.7
MSA1C-(Si,A)	62.5 $\pm$ 10.2	62.8 $\pm$ 5.8	60.4 $\pm$ 11.0	45.7 $\pm$ 11.9
MSA1C-(nSi,nA)	27.0 $\pm$ 10.3	23.7 $\pm$ 6.3	20.0 $\pm$ 4.6	22.3 $\pm$ 3.5
MSA1 C-(nSi,A)	20.2 $\pm$ 0.7	12.3 $\pm$ 4.9	25.9 $\pm$ 6.0	20.6 $\pm$ 5.0
WR	11.8 $\pm$ 4.0	8.8 $\pm$ 8.1	14.2 $\pm$ 1.3	3.8 $\pm$ 4.9

The assays were performed in duplicate three times each.

## Discussion

The C-terminal region of the MSA1 protein was inserted into the vaccinia virus to investigate the immune response produced by this antigen. Four variations of the MSA1 fragment were used to create constructs which contained neither, one or both of the original MSA1 N-terminal signal sequence and the original C-terminal anchor sequence. Data from immunostaining (date not shown) and Western blot assays (Figure 7) indicated that all four of the recombinant vaccinia virus constructs were expressed in the infected cells. The apparent molecular weight of the MSA1C-(Si,A) construct is less than expected and may be due to proteolytic cleavage of the protein during export. This size discrepancy in the recombinant protein is only seen when the anchor region is present in addition to the signal sequence and it is possible that the presence of both of the two regions is necessary for the processing of the protein. The Western blot also reveals multiple bands from the MSA1C-(Si,nA) and MSA1C-(Si,A) proteins and these may be different glycosylation forms. Such a pattern is seen only in the two constructs containing the signal sequence, implying that the protein is glycosylated after entering the Golgi.

The two constructs with the signal sequence are expressed on the cell surface, whereas the two constructs

without the signal sequence are not. These data indicate that the signal sequence is necessary for proper export of the expressed recombinant protein to the cell surface. Furthermore, the data show that the signal region alone is sufficient for cell surface expression. It is possible that once the protein has entered the secretory pathway, because of the signal sequence, there is resultant cell surface expression. The strength and duration of this cell surface expression appears to be greater when the protein contains the anchor region in addition to the signal region and this may be due to hydrophobic interactions. Data indicate also that the protein is not secreted externally and thus presumably remains bound to the cell surface. However, the construct with only the signal sequence elicits a weaker immune response than does the construct with both the signal and anchor regions. The anchor region may be necessary for proper protein conformation which is necessary for a high immune response.

Immunofluoresence data illustrate that antibodies induced by the MSA1C-(Si,nA) and MSA1C-(Si,A) constructs recognize the parasite in vitro. This indicates that the recombinant protein expressed by the vaccinia virus is indeed very similar, if not identical, to the native parasite MSA1 C-terminus. Antibodies targeting the vaccinia viruses indicate that all four recombinant virus constructs as well as WR were administered at approximately the same level. Therefore the differences of the antibody responses of these four constructs is due to the primary sequence of the protein, not varying levels of vaccinia virus. The recombinant protein containing

both the signal and anchor regions elicits the greatest immune response and this suggests that both the signal and anchor sequences are advantageous for optimal expression of the MSA-1 C-terminal region. Furthermore, antibodies to the protein containing both the signal and anchor sequences most effectively inhibit invasion of erythrocytes by parasites. Although 62% inhibition of invasion may seem only a partial inhibition, these invasion assays were conducted with a 3% starting parasitemia, whereas most other studies are done at approximately 0.3%. A higher starting parasitemia may reduce the inhibition because of the large numbers of merozoites released.

This study has shown that the MSA1C-(Si,A) construct expresses a functional protein which possesses the proper signal sequence and the proper anchor sequence for correct cell surface expression. Furthermore, the antibodies produced by mice and rabbits immunized with the recombinant vaccinia virus are able to block parasite invasion in vitro.

**DEPOSITS**

The following have been deposited with the American type Culture Collection located at 12301 Parklawn Drive, Rockville, Maryland 20852 pursuant to the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure. All restrictions on the availability of the materials deposited will be irrevocably removed upon the issuance of a patent thereon.

**Microorganism****ATCC Designation**

Recombinant Vaccinia Virus

VR-2518

r.v.v-MSA.C (Si,A)

While the invention has been described in its preferred embodiment, it is to be understood that the words which have been used are words of description rather than limitation and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the invention in its broader aspects.



**Claims**

1. A vaccine comprising an expression vector comprising a nucleotide sequence which encodes for an immunogenic MSA1 peptide in combination with a mammalian signal sequence or mammalian anchor sequence.
2. The vaccine according to claim 1 wherein said MSA1 peptide is combined with a signal sequence and an anchor sequence.
3. The vaccine according to claim 2 wherein said MSA1 peptide is a carboxy-terminal MSA1 peptide.
4. The vaccine according to claim 3 wherein said MSA1 peptide is a carboxy-terminal MSA1 peptide.
5. The vaccine according to claim 5 wherein said carboxy-terminal MSA1 peptide is a 593 amino acid peptide corresponding to amino acids 1047 to 1640 of MSA1.
6. The vaccine according to claim 6 wherein said signal sequence is MKIIFFLCSFLFFIINTOC or MKIIF-FLCSFLFFIINTOCVTHESYOELVKKLEALEDVLTGYSLFOKEKMVLNE.
7. The vaccine according to claim 6 wherein said anchor sequence is FLGISFLLILMLILYSFI.
8. A method of vaccinating a patient against malaria

comprising administering an effective amount of a recombinant vaccinia virus capable of expressing MSA1 peptide after administration of said vaccine to a patient.

9. The method according to claim 9 wherein said MSA1 peptide is combined with at least one peptide selected from a signal sequence and an anchor sequence.

10. The method according to claim 10 wherein said MSA1 peptide is combined with a signal peptide and an anchor peptide.

11. The method according to claim 10 wherein said MSA1 peptide is a carboxy-terminal MSA1 peptide.

12. The method according to claim 11 wherein said MSA1 peptide is a carboxy-terminal MSA1 peptide.

13. The method according to claim 12 wherein said carboxy-terminal MSA1 peptide is a 593 amino acid peptide corresponding to amino acids 1047 to 1640 of MSA1.

14. The method according to claim 11 wherein said signal sequence is MKIIFFLCSFLFFIINTOC or MKIIF-FLCSFLFFIINTOCVTHESYOELVKKLEALEDAVLTGYSLFOKEKMVLNE.

15. The method according to claim 11 wherein said anchor sequence is FLGISFLLILMLILYSFI.

16. A chimeric peptide sequence comprising:

- a) an immunogenic MSA1 peptide;
- b) an anchor sequence peptide; and
- c) a signal sequence peptide.

17. The chimeric peptide according to claim 16 wherein said MSA1 peptide is a carboxy-terminal MSA1 peptide.

18. The chimeric peptide according to claim 17 wherein said carboxy-terminal MSA1 peptide is a 593 amino acid peptide corresponding to amino acids 1047 to 1640 of MSA1.

19. The chimeric peptide according to claim 16 wherein said signal sequence is MKIIFFLCSFLFFIINTOC or MKIIF-FLCSFLFFIINTOCVTHESYOELVKKLEALEDAVLTGYSLFOKEKMLVNE.

20. The chimeric peptide according to claim 16 wherein said anchor sequence is FLGISFLLILMLILYSFI.

21. An expression vector comprising a nucleotide sequence which encodes for an immunogenic MSA1 peptide and a mammalian signal sequence or a mammalian anchor sequence.

22. The vector according to claim 21 encoding for said MSA1 peptide in combination with a signal sequence and an anchor sequence.

23. The vector according to claim 21 wherein said MSA1 peptide is a carboxy-terminal MSA1 peptide.

24. The vector according to claim 22 wherein said MSA1 peptide is a carboxy-terminal MSA1 peptide.

25. The vector according to claim 21 wherein said carboxy-terminal MSA1 peptide is a 593 amino acid peptide corresponding to amino acids 1047 to 1640 of MSA1.

26. The vector according to claim 22 wherein said signal sequence is MKIIFFLCSFLFFIINTOC or MKIIF-FLCSFLFFIINTOCVTHESYOELVKKLEALEDVLTGYSLFOKEKMLVNE.

27. The vector according to claim 22 wherein said anchor sequence is FLGISFLLILMLILYSFI.

28. A vaccinia viral vector according to claim 22.

29. A vaccinia viral vector according to claim 23.

30. A vaccinia viral vector according to claim 24.


31. A vaccinia viral vector according to claim 26.


32. A vaccine comprising an immunogenically effective amount of the peptide according to claim 17 administered in combination with a pharmaceutically acceptable carrier, excipient or additive.

33. A DNA sequence corresponding substantially to the

sequence set forth in Figure 2, Figure 3 or Figure 4.

34. The DNA sequence of claim 33 corresponding substantially to the sequence set forth in Figure 2.



**Fig. 1B**

3/13

## GENE SEQUENCE OF MSA1C-(Si,A)

```

ATG AAGATCATAT TCTTTTATG TTCATTCTT TTTTATTATTA TAAATACACA
ATGTGTAACA CATGAAAGTT ATCAAGAACT TGTCAAAAA CTAGAAGCTT TAGAAGATGC
AGTATTGACA GGTATAGTT TATTTCAAAA GGAAAAAATG GTATTAAATG
AATTGAATTC ACTTAATAAC CCAAAGCATG TATTACAAA CTTTCTGTT
TTCTTTAACA AAAAAAAGA AGCTGAAATA GCAGAACTG AAAACACATT
AGAAACACA AAAATATTAT TGAAACATTA TAAAGGACTT GTTAAATATT
ATAATGGTGA ATCATCTCCA TTA AAAACTT TAAGTGAAGA ATCAATTCAA
ACAGAAGATA ATTATGCCAG TTTAGAAAAC TTTAAAGTAT TAAGTAAATT
AGAAGGAAAA TTAAAGGATA ATTTAAATTT AGAAAAGAAA AAATTATCAT
ACTTATCAAG TGGATTACAT CATTTAATTG CTGAATTAAA AGAAGTAATA
AAAAATAAAA ATTATACAGG TAATTCTCCA AGTGAAAATA ATACGGATGT
TAACAATGCA TTAGAATCTT ACAAAAATT TCTCCAGAA GGAACAGATG
TTGCAACAGT TGTAAGTGAA AGTGGATCCG ACACATTAGA ACAAAGTCAA
CCAAAGAAAC CAGCATCAAC TCATGTAGGA GCAGAGTCTA ACACAATAAC
AACATCACAA AATGTCGATG ATGAAGTAGA TGACGTAATC ATAGTACCTA
TATTTGGAGA ATCCGAAGAA GATTATGATG ATTTAGGACA AGTAGTAACA
GGAGAAGCAG TAACTCCTTC CGTAATTGAT AACATACTTT CTAAAATTGA
AAATGAATAT GAGGTTTTAT ATTTAAAACC TTTAGCAGGT GTTTATAGAA
GTTTAAAAAA ACAATTAGAA AATAACGTTA TGACATTTAA TGTTAATGTT
AAGGATATTT TAAATTCACG ATTTAATAAA CGTGAAAATT TCAAAAATGT
TTTAGAATCA GATTTAATTC CATATAAAGA TTAAACATCA AGTAATTATG
TTGTCAAAGA TCCATATAAA TTTCTTAATA AAGAAAAAAG AGATAAATTC
TTAAGCAGTT ATAATTATAT TAAGGATTCA ATAGATACGG ATATAAATTT
TGCAAATGAT GTTCTTGGAT ATTATAAAAT ATTATCCGAA AAATATAAAT
CAGATTTAGA TTCAATTAAA AAATATATCA ACGACAAACA AGGTGAAAAT
GAGAAATACC TTCCCTTTTT AAACAATATT GAGACCTTAT ATAAAACAGT
TAATGATAAA ATTGATTTAT TTGTAATTCA TTTAGAAGCA AAAGTTCTAA
ATTATACATA TGAGAAATCA AACGTAGAAG TTAAAATAAA AGAACTTAAT
TACTTAAAAA CAATTCAAGA CAAATTGGCA GATTTTAAAA AAAATAACAA
TTTCGTTGGA ATTGCTGATT TATCAACAGA TTATAACCAT AATAACTTAT
TGACAAAGTT CCTTAGTACA GGTATGGTTT TTGAAAATCT TGCTAAAACC
GTTTTATCTA ATTTACTTGA TGGAACTTG CAAGGTATGT TAAACATTTT
ACAACACCAA TGCGTAAAAA AACAATGTCC ACAAATTCTT GGATGTTTCA
GACATTTAGA TGAAAGAGAA GAATGTAAAT GTTTATTAAA TTACAAACAA
GAAGGTGATA AATGTGTTGA AAATCCAAAT CCTACTTGTA ACGAAAATAA
TGGTGGATGT GATGCAGATG CCAAATGTAC CGAAGAAGAT TCAGGTAGCA
ACGGAAGAA AATCACATGT GAATGTACTA AACCTGATTC TTATCCACTT
TTCGATGGTA TTTTCTGCAG TTCCTCTAAC TTCTTAGGAA TATCATTCTT
ATTAATACTC ATGTTAATAT TATACAGTTT CATTTAA

```

Fig. 2



4/13

## GENE SEQUENCE OF MSA1C-(Si,nA)

```

ATG  AAGATCATAT TCTTTTATG TTCATTCTT TTTTATTATA TAAATACACA
ATGTGTAACA CATGAAAGTT ATCAAGAACT TGTCAAAAAA CTAGAAGCTT TAGAAGATGC
AGTATTGACA GGTTATAGTT TATTTCAAAA GGAAAAAATG GTATTAAATG
AATTGAATTC ACTTAATAAC CCAAAGCATG TATTACAAAA CTTTCTGTGTT
TTCTTTAACA AAAAAAAGA AGCTGAAATA GCAGAACTG AAAACACATT
AGAAAACACA AAAATATTAT TGAAACATTA TAAAGGACTT GTTAAATATT
ATAATGGTGA ATCATCTCCA TTAAAAAATT TAAGTGAAGA ATCAATTCAA
ACAGAAGATA ATTATGCCAG TTTAGAAAAC TTTAAAGTAT TAAGTAAATT
AGAAGGAAAA TTAAAGGATA ATTTAAATTT AGAAAAGAAA AAATTATCAT
ACTTATCAAG TGGATTACAT CATTTAATTG CTGAATTAAA AGAAGTAATA
AAAAATAAAA ATTATACAGG TAATTCTCCA AGTGAAAATA ATACGGATGT
TAACAATGCA TTAGAATCTT ACAAAAAATT TCTCCCAGAA GGAACAGATG
TTGCAACAGT TGTAAGTGAA AGTGGATCCG ACACATTAGA ACAAAGTCAA
CCAAAGAAAC CAGCATCAAC TCATGTAGGA GCAGAGTCTA ACACAATAAC
AACATCACAA AATGTCGATG ATGAAGTAGA TGACGTAATC ATAGTACCTA
TATTTGGAGA ATCCGAAGAA GATTATGATG ATTTAGGACA AGTAGTAACA
GGAGAAGCAG TAACTCCTTC CGTAATTGAT AACATACTTT CTAAAATTGA
AAATGAATAT GAGGTTTTAT ATTTAAAACC TTTAGCAGGT GTTTATAGAA
GTTTAAAAAA ACAATTAGAA AATAACGTTA TGACATTTAA TGTTAATGTT
AAGGATATTT TAAATTCACG ATTTAATAAA CGTGAAAATT TCAAAAATGT
TTTAGAATCA GATTTAATTC CATATAAAGA TTTAACATCA AGTAATTATG
TTGTCAAAGA TCCATATAAA TTTCTTAATA AAGAAAAAAG AGATAAATTC
TTAAGCAGTT ATAATTATAT TAAGGATTCA ATAGATACGG ATATAAATTT
TGCAAATGAT GTTCTTGGAT ATTATAAAAT ATTATCCGAA AAATATAAAT
CAGATTTAGA TTCAATTAAA AAATATATCA ACGACAAACA AGGTGAAAAT
GAGAAATACC TTCCCTTTTT AAACAATATT GAGACCTTAT ATAAAACAGT
TAATGATAAA ATTGATTTAT TTGTAATTCA TTTAGAAGCA AAAGTTCTAA
ATTATACATA TGAGAAATCA AACGTAGAAG TTAAAAATAA AGAACTTAAT
TACTTAAAAA CAATTCAAGA CAAATTGGCA GATTTTAAAA AAAATAACAA
TTTCGTTGGA ATTGCTGATT TATCAACAGA TTATAACCAT AATAACTTAT
TGACAAAGTT CCTTAGTACA GGTATGGTTT TTGAAAATCT TGCTAAAACC
GTTTTATCTA ATTTACTTGA TGGAACTTG CAAGGTATGT TAAACATTTC
ACAACACCAA TGCGTAAAAA AACAATGTCC ACAAATTTCT GGATGTTTCA
GACATTTAGA TGAAAGAGAA GAATGTAAAT GTTTATTAAA TTACAAACAA
GAAGGTGATA AATGTGTTGA AAATCCAAAT CCTACTGTA ACGAAAATAA
TGGTGGATGT GATGCAGATG CCAAATGTAC CGAAGAAGAT TCAGGTAGCA
ACGGAAGAA AATCACATGT GAATGTACTA AACCTGATTC TTATCCACTT
TTCGATGGTA TTTTCTGCAG TTCCTCTAAC TAA

```

Fig. 3

5/13

## GENE SEQUENCE OF MSA1C-(nSi,A)

```

ATGGTAACA CATGAAAGTT ATCAAGAACT TGTCAAAAA CTAGAAGCTT TAGAAGATGC
AGTATTGACA GGTTATAGTT TATTTCAAAA GGAAAAAATG GTATTAATG
AATTGAATTC ACTTAATAAC CCAAAGCATG TATTACAAAA CTTTCTGTGTT
TTCTTTAACA AAAAAAAGA AGCTGAAATA GCAGAACTG AAAACACATT
AGAAAACACA AAAATATTAT TGAAACATTA TAAAGGACTT GTTAAATATT
ATAATGGTGA ATCATCTCCA TTAAAAACTT TAAGTGAAGA ATCAATTCAA
ACAGAAGATA ATTATGCCAG TTTAGAAAAC TTAAAGTAT TAAGTAAATT
AGAAGGAAAA TTAAAGGATA ATTTAAATTT AGAAAAGAAA AAATTATCAT
ACTTATCAAG TGGATTACAT CATTTAATTG CTGAATTAAA AGAAGTAATA
AAAAATAAAA ATTATACAGG TAATTCTCCA AGTGAAAATA ATACGGATGT
TAACAATGCA TTAGAATCTT ACAAAAAATT TCTCCCAGAA GGAACAGATG
TTGCAACAGT TGTAAGTGAA AGTGGATCCG ACACATTAGA ACAAAGTCAA
CCAAAGAAAC CAGCATCAAC TCATGTAGGA GCAGAGTCTA ACACAATAAC
AACATCACAA AATGTCGATG ATGAAGTAGA TGACGTAATC ATAGTACCTA
TATTTGGAGA ATCCGAAGAA GATTATGATG ATTTAGGACA AGTAGTAACA
GGAGAAGCAG TAACTCCTTC CGTAATTGAT AACATACTTT CTAAAAATTGA
AAATGAATAT GAGGTTTTAT ATTTAAAACC TTTAGCAGGT GTTTATAGAA
GTTTAAAAAA ACAATTAGAA AATAACGTTA TGACATTTAA TGTTAATGTT
AAGGATATTT TAAATTCACG ATTTAATAAA CGTGAAAATT TCAAAAATGT
TTTAGAATCA GATTTAATTC CATATAAAGA TTTAACATCA AGTAATTATG
TTGTCAAAGA TCCATATAAA TTTCTTAATA AAGAAAAAAG AGATAAATTC
TTAAGCAGTT ATAATTATAT TAAGGATTCA ATAGATACGG ATATAAATTT
TGCAAATGAT GTTCTTGGAT ATTATAAAAT ATTATCCGAA AAATATAAAT
CAGATTTAGA TTCAATTAAA AAATATATCA ACGACAAACA AGGTGAAAAT
GAGAAATACC TTCCCTTTTT AAACAATATT GAGACCTTAT ATAAAACAGT
TAATGATAAA ATTGATTTAT TTGTAATTCA TTTAGAAGCA AAAGTTCTAA
ATTATACATA TGAGAAATCA AACGTAGAAG TTAAAATAAA AGAACTTAAT
TACTTAAAAA CAATTCAAGA CAAATTGGCA GATTTTAAAA AAAATAACAA
TTTCGTTGGA ATTGCTGATT TATCAACAGA TTATAACCAT AATACTTAT
TGACAAAGTT CCTTAGTACA GGTATGGTTT TTGAAAATCT TGCTAAAACC
GTTTTATCTA ATTTACTTGA TGGAACTTG CAAGGTATGT TAAACATTTT
ACAACACCAA TGCGTAAAAA AACAATGTCC ACAAATTCT GGATGTTTCA
GACATTTAGA TGAAAGAGAA GAATGTAAAT GTTTATTAAA TTACAAACAA
GAAGGTGATA AATGTGTTGA AAATCCAAAT CCTACTTGTA ACGAAAATAA
TGGTGGATGT GATGCAGATG CCAAATGTAC CGAAGAAGAT TCAGGTAGCA
ACGGAAGAA AATCACATGT GAATGTACTA AACCTGATTC TTATCCACTT
TTCGATGGTA TTTTCTGCAG TTCCTCTAAC TTCTTAGGAA TATCATTCTT
ATTAATACTC ATGTTAATAT TATACAGTTT CATTTAA

```

Fig. 4

6/13

## GENE SEQUENCE OF MSA1C-(nSi,nA)


```

ATGGTAACA CATGAAAGTT ATCAAGAAGT TGTCAAAAAA CTAGAAGCTT TAGAAGATGC
AGTATTGACA GGTTATAGTT TATTTCAAAA GGAAAAAATG GTATTAAATG
AATTGAATTC ACTTAATAAC CCAAAGCATG TATTACAAAA CTTTTCTGTT
TTCTTTAACA AAAAAAAGA AGCTGAAATA GCAGAACTG AAAACACATT
AGAAAACACA AAAATATTAT TGAAACATTA TAAAGGACTT GTTAAATATT
ATAATGGTGA ATCATCTCCA TTA AAAACTT TAAGTGAAGA ATCAATTCAA
ACAGAAGATA ATTATGCCAG TTTAGAAAAC TTTAAAGTAT TAAGTAAATT
AGAAGGAAAA TTAAAGGATA ATTTAAATTT AGAAAAGAAA AAATTATCAT
ACTTATCAAG TGGATTACAT CATTTAATTG CTGAATTAAA AGAAGTAATA
AAAAATAAAA ATTATACAGG TAATTCTCCA AGTGAATAA ATACGGATGT
TAAACAATGCA TTAGAATCTT ACAA AAAAATT TCTCCAGAA GGAACAGATG
TTGCAACAGT TGTAAGTGAA AGTGGATCCG ACACATTAGA ACAAAGTCAA
CCAAAGAAAC CAGCATCAAC TCATGTAGGA GCAGAGTCTA ACACAATAAC
AACATCACAA AATGTGATG ATGAAGTAGA TGACGTAATC ATAGTACCTA
TATTTGGAGA ATCCGAAGAA GATTATGATG ATTTAGGACA AGTAGTAACA
GGAGAAGCAG TAACTCCTTC CGTAATTGAT AACATACTTT CTAAAATTGA
AAATGAATAT GAGGTTTAT ATTTAAAACC TTTAGCAGGT GTTTATAGAA
GTTTAAAAAA ACAATTAGAA AATAACGTTA TGACATTTAA TGTTAATGTT
AAGGATATTT TAAATTCACG ATTTAATAAA CGTGA AAAATT TCAAAAATGT
TTTAGAATCA GATTTAATTC CATATAAGA TTTAACATCA AGTAATTATG
TTGTCAAAGA TCCATATAAA TTTCTTAATA AAGAAAAAAG AGATAAATTC
TTAAGCAGTT ATAATTATAT TAAGGATTCA ATAGATACGG ATATAAATTT
TGCAAAATGAT GTTCTTGAT ATTATAAAAT ATTATCCGAA AAATATAAAT
CAGATTTAGA TTCAATTAAA AAATATATCA ACGACAAACA AGGTGAAAAT
GAGAAATACC TTCCCTTTT AAACAATATT GAGACCTTAT ATAAAACAGT
TAATGATAAA ATTGATTTAT TTGTAATTCA TTTAGAAGCA AAAGTTCTAA
ATTATACATA TGAGAAATCA AACGTAGAAG TTA AAAATAAA AGA ACTTAAT
TACTTAAAA CAATTCAAGA CAAATTGGCA GATTTTAAAA AAAATAACAA
TTTCGTTGGA ATTGCTGATT TATCAACAGA TTATAACCAT AATAACTTAT
TGACAAAGTT CCTTAGTACA GGTATGGTTT TTGAAAATCT TGCTAAAACC
GTTTTATCTA ATTTACTTGA TGGAAACTTG CAAGGTATGT TAAACATTTT
ACAACACCAA TGCGTAAAAA AACAATGTCC ACAA AATTCT GGATGTTTCA
GACATTTAGA TGAAAGAGAA GAATGTAAAT GTTTATTAAA TTACAAACAA
GAAGGTGATA AATGTGTTGA AAATCCAAAT CCTACTTGTA ACGAAAATAA
TGGTGGATGT GATGCAGATG CCAAATGTAC CGAAGAAGAT TCAGGTAGCA
ACGGAAGAA AATCACATGT GAATGTACTA AACCTGATTC TTATCCACTT
TTCGATGGTA TTTTCTGCAG TTCCTCTAAC TAA

```

Fig. 5

7/13

**Fig. 6**

8/13






Fig. 7

9/13


**Fig. 8A**




**Fig. 8B**




**Fig. 8C**




**Fig. 8D**



**Fig. 8E**




**Fig. 8F**




10/13


**Fig. 8G**




**Fig. 8H**



**Fig. 8I**



**Fig. 8J**



11/13





Fig. 9  
Days Post-infection





**Fig. 10**

13/13




Fig. 11

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/01395

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 39/00; A01N 43/04, 63/00; C12P 21/06  
US CL : 424/185.1; 514/44; 435/69.1; 424/93.21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/185.1; 514/44; 435/69.1; 424/93.21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, STN

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 5,585,268 A (KNAPP et al.) 17 December 1996, column 1, lines 40-65.	1-34
Y	HUI et al. Immunological Cross-Reactivity of the C-Terminal 42-Kilodalton Fragment of Plasmodium falciparum Merozoite Surface Protein 1 Expressed in Baculovirus. Infection and Immunity. August 1993, Vol. 61, No. 8, pages 3403-3411, especially page 3408.	1-34

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 APRIL 1997

Date of mailing of the international search report

24 JUN 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVE NGUYEN

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/01395

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.